As filed with the Securities and Exchange Commission on August 8, 2019

Registration No. ________

 

 

 

UNITED STATES

SECURiTIES AND EXChANGE COMMISSION

Washington, D.C. 20549

 

FORM F-3

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

 

B.O.S. BETTER ONLINE SOLUTIONS LTD.

(Exact name of Registrant as specified in its charter)

 

Israel   Not Applicable
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

20 Freiman Street

Rishon LeZion, 75100, Israel

(+972) 3-954-1000

(Address and Telephone Number of Registrant's principal executive offices)

 

B.O.S. Better Online Solutions Ltd.

c/o Ruby-tech, Inc.

147-20 184 th St.,

Jamaica NY 11413, USA.

508-655-2312

(Name, address and telephone number of agent for service)

 

Copies To:

 

Brian Brodrick, Esq.

Phillips Nizer LLP

485 Lexington Avenue

New York, New York 10017

(212) 841-0700

Shlomo Landress, Adv.

Gornitzky & Co.

45 Rothschild Boulevard

Tel Aviv 6578403, Israel

972-3-710-9191

 

Approximate date of commencement of proposed sale to the public : From time to time after this registration statement becomes effective.

 

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, please check the following box. ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

 

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

 

Emerging growth company ☐

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act . ☐

 

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

 

 

 

CALCULATION OF REGISTRATION FEE

 

Title of Each Class of Securities to be Registered

 

Amount to be
Registered (1)(2)

    Proposed Maximum Offering Price Per Share (3)     Proposed Maximum Aggregate Offering Price     Amount of Registration
Fee
 
                         
Ordinary Shares, nominal value NIS 80.00 per share)     400,000       2.88     $ 1,152,000     $ 139.62  
Ordinary Shares, nominal value NIS 80.00 per share, underlying warrants issued to a selling shareholder(4)     300,000       3.30     $ 990,000     $ 119.98  
Total     700,000                     $ 259.60  

 

(1) Pursuant to Rule 416 of the Securities Act of 1933, as amended, this registration statement also includes additional Ordinary Shares issuable upon stock splits, stock dividends or similar transactions.
(2) Represents Ordinary Shares that may be sold from time to time pursuant to this registration statement by the Selling Shareholders named herein.
(3) Estimated, solely for purposes of calculating the registration fee for the Ordinary Shares being registered, based upon the average of the high and low prices of the Ordinary Shares of the registrant on the Nasdaq Capital Market as of August 5, 2019 pursuant to Rule 457(c) under the Securities Act.
(4) Represents shares issuable upon exercise of warrants that were issued to the Selling Shareholders. The registration fee for the warrant shares has been calculated pursuant to Rule 457(g) under the Securities Act based on the exercise price of the warrants of $3.30 per Ordinary Share.

 

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 (the “Securities Act”) or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine .

 

 

 

 

 

 

THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THESE SECURITIES MAY NOT BE SOLD UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.

 

Preliminary Prospectus

 

Subject to completion, dated August 8, 2019

 

700,000 Ordinary Shares Offered by Selling Shareholders

 

B.O.S. BETTER ONLINE SOLUTIONS LTD.

 

This prospectus relates to the resale of up to 400,000 of our Ordinary Shares by certain selling shareholders (the “Selling Shareholders”), that purchased the shares from us pursuant to a Securities Purchase Agreement, dated as of May 16, 2019 (the “ Agreement ”) for a total purchase price of $1,000,000.

 

In addition, this prospectus relates to the resale by the Selling Shareholders (excluding RHK Capital affiliates) of up to 240,000 Ordinary Shares that are issuable upon exercise of warrants (the “ Warrants ”), with an exercise price of $3.30 per Ordinary Share, that we issued to the Selling Shareholders pursuant to the Agreement. The Warrants shall be exercisable for 3.5 years and shall be subject to a 3-year vesting period as follows: one third of the Warrants shall vest annually (upon the lapse of 12 months, 24 months and 36 months from issuance), provided that on the applicable vesting date the investor did not sell any of the Ordinary Shares purchased under the Agreement. Vesting of all of the Warrants shall be accelerated in the event that any one or more shareholders acting together acquire a block of 40% of the Company’s issued and outstanding share capital. The prospectus also relates to the resale by RHK Capital affiliates of up to 60,000 Ordinary Shares that are issuable upon  exercise of  warrants with an exercise price of $3.30 per Ordinary Share (the “ RHK Warrants ”). The RHK Warrants shall be exercisable from 3.5 years after the lapse of 6 months from issuance.

 

We will not receive any of the proceeds from the sale of the ordinary shares offered by the Selling Shareholders.  We will, however, receive proceeds upon exercise of the Warrants and RHK Warrants issued to the Selling Shareholders.

 

The Ordinary Shares purchased under the Agreement shall be subject to a contractual six-month lock-up from the closing date of the Agreement. In connection with the Agreement, the Company has paid to RHK Capital (a subsidiary of Advisory Group Equity Services, Ltd. doing business as RHK Capital, “ RHK Capital ”) a sales commission of $40,000, and issued to RHK Capital affiliates a total of 60,000 warrants with an exercise price of $3.30 per ordinary share.

 

The Selling Shareholders may sell the Ordinary Shares, from time to time, in regular brokerage transactions, in transactions directly with market makers or in privately negotiated transactions. For additional information on the methods of sale that may be used by the Selling Shareholders, see the section titled “Plan of Distribution” beginning on page 19.

 

Our Ordinary Shares are traded on the NASDAQ Capital Market under the symbol “BOSC”. On August 5, 2019, the last reported sale price of our Ordinary Shares on the NASDAQ Capital Market was $2.910 per share. You are urged to obtain current market quotations for the Ordinary Shares.

 

You should read both this prospectus and any prospectus supplement, together with the additional information described under the heading “Incorporation of Certain Documents by Reference” before you decide to invest in our Ordinary Shares.

 

INVESTING IN OUR ORDINARY SHARES INVOLVES A HIGH DEGREE OF RISK. SEE “RISK FACTORS” ON PAGE 3 OF THIS PROSPECTUS TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE PURCHASING OUR ORDINARY SHARES.

 

To the best of our knowledge, no underwriter or person has been engaged to facilitate the sale of Ordinary Shares in this offering. The Securities and Exchange Commission (the “SEC” or the “Commission”), may take the view that, under certain circumstances, any broker-dealers or agents that participate in the distribution of the Ordinary Shares may be deemed to be “underwriters” within the meaning of the Securities Act. Commissions, discounts or concessions received by any such broker-dealer or agent may be deemed to be underwriting commissions under the Securities Act.

 

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this registration statement. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is August 8, 2019 

 

 

 

TABLE OF CONTENTS

 

Item   Page
     
Prospectus Summary   1
The Offering   2
Risk Factors   3
Forward-Looking Statements   16
Capitalization and Indebtedness   17
Use of Proceeds   17
Selling Shareholder   18
Plan of Distribution   19
Description of Ordinary Shares   21
Offering Expenses   23
Validity of Securities   23
Experts   23
Where You Can Find More Information   23
Incorporation of Certain Documents by Reference   24
Enforceability of Civil Liabilities   25

 

You should rely only on the information contained or incorporated by reference in this prospectus or any supplement. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and any underwriter or agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

 

i

 

PROSPECTUS SUMMARY

 

About This Prospectus

 

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf process, the Selling Shareholders referred to in this prospectus may sell up to 700,000 Ordinary Shares, from time to time, subject to a contractual six-month lock-up from the closing date of the Agreement.

 

This prospectus does not contain all of the information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. Accordingly, you should refer to the registration statement and its exhibits for further information about us and our Ordinary Shares. Copies of the registration statement and its exhibits are on file with the SEC. Statements contained in this prospectus concerning the documents we have filed with the SEC are not intended to be comprehensive, and in each instance we refer you to a copy of the actual document filed as an exhibit to the registration statement or otherwise filed with the SEC.

 

We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. The Selling Shareholders are offering to sell, and seeking offers to buy our Ordinary Shares only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of Ordinary Shares.

 

Unless the context otherwise requires, all references in this prospectus to “BOS,” “we,” “our,” “our company,” “us” and the “Company” refer to B.O.S. Better Online Solutions Ltd. and its consolidated subsidiaries.

 

All references in this prospectus to “Ordinary Shares” refer to our Ordinary Shares, nominal value NIS 80.00 per share.

 

All references in this prospectus to “dollars” or “$” are to United States Dollars.

 

All references in this prospectus to “shekels” or “NIS” are to New Israeli Shekels.

 

The Company

 

We were incorporated in Israel in 1990 and are subject to the Israeli Companies Law 1999 – 5759 (the “ Israeli Companies Law ”). Our executive offices, shipping and service operations are located in Israel. Our address in Israel is 20 Freiman Street, Rishon LeZion, 75100, Israel.

 

Our address in the United States is B.O.S. Better Online Solutions Ltd. c/o Ruby-tech, Inc. 147-20 184 th St., Jamaica NY 11413, USA, telephone 508-655-2312

 

Our telephone number is 972-3-954-2000 and our website address is www.boscom.com. Our subsidiaries’ websites are: BOS-Odem Ltd. (“Odem”) - www.odem.co.il; and BOS-Dimex Ltd. (“Dimex”)– www.dimex.co.il. The information contained on, or linked from, our websites is not a part of this prospectus.

 

B.O.S is a global provider of RFID and Robotic systems and of Supply Chain solutions to enterprises. BOS operates through two business divisions:

 

Intelligent Robotics and RFID Division (formerly known as our RFID and Mobile Solutions Division), which offers smart automation systems and tailor made robotics for industrial processes, logistics and retail stores.

 

Supply Chain division, which provides electronic components mainly for the aerospace, defense and other industries worldwide, including electronic components services of consolidation from a vast number of suppliers, long term scheduling and kitting.

1

 

THE OFFERING

 

General

 

This prospectus relates to the offering by the Selling Shareholders of up to 700,000 Ordinary Shares.

 

The Ordinary Shares purchased under the Agreement shall be subject to a contractual six-month lock-up from the closing date of the Agreement. In connection with the Agreement, the Company has paid to RHK Capital (a unit of Advisory Group Equity Services, Ltd.) a sales commission of $40,000, and issued to RHK Capital affiliates a total of 60,000 warrants with an exercise price of $3.30 per ordinary share.

 

BOS is filing the registration statement of which this prospectus is a part, or the Registration Statement, at this time to fulfill its contractual obligations to do so. Registration of the Ordinary Shares does not necessarily mean that all or any portion of such Ordinary Shares will be offered for sale by the Selling Shareholders.

 

Securities Purchase Agreement (the “Agreement”)

 

On May 16, 2019 we entered into and closed a Securities Purchase Agreement with Selling Shareholders for the sale of 400,000 Ordinary Shares at a price of $2.50 per share, resulting in gross proceeds of $1 million.

 

In addition, we issued, to the Selling Shareholders 240,000 warrants with an exercise price of $3.30 per Ordinary Share (the “ Warrants ”). The Warrants shall be exercisable for 3.5 years and shall be subject to a 3 vesting period as follows: one third of the warrants shall vest annually (upon the lapse of 12 months, 24 months and 36 months from issuance), provided that on the applicable vesting date the investor did not sell any of the Ordinary Shares purchased under the Agreement. Vesting of all of the Warrants shall be accelerated in the event that any one or more shareholders acting together acquire a block of 40% of the Company’s issued and outstanding share capital.

 

We are now registering for resale by the Selling Shareholders Ordinary Shares that we have sold to them under the Agreement, including the Ordinary shares issuable upon exercise of the Warrants and the RHK Warrants.

2

 

 

RISK FACTORS

 

You should carefully consider the risks described below and all the information contained or incorporated by reference into this prospectus before making an investment decision regarding our Ordinary Shares. The risks described below are not the only risks facing our company. Additional risks and uncertainties that we are not aware of or that we currently believe are immaterial may also adversely affect our business, financial condition, results of operation and liquidity. The trading price of our Ordinary Shares could decline due to any of these risks, and you may lose all or part of your investment.

 

Risks relating to our financial results and capital structure:

 

We require a significant amount of cash to satisfy our debt obligations. If we fail to generate sufficient cash flow from operations, we may need to renegotiate or refinance our debt, obtain additional financing, postpone capital expenditures or sell assets.

 

As of December 31, 2018 we had $2.3 million in long-term debt (including current maturities of $467,000) and no short term bank loans.

 

We depend mainly on cash generated by continuing operating activities to make payments on our debt. We cannot assure you that we will generate sufficient cash flow from operations to make the scheduled payments on our debt. Our ability to meet our debt obligations will depend on whether we can successfully implement our business strategy, as well as on economic, financial, competitive and technical factors (See “Item 5B. Liquidity and Capital Resources” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2018 (our “ Form 20-F ”).

 

Some of the factors are beyond our control, such as economic conditions in the markets where we operate or intend to operate, changes in our customers’ demand for products that we sell, and pressure from existing and new competitors. Also, because part of our loans bear interest at floating rates, we are susceptible to an increase in interest rates (See “Item 11. Quantitative and Qualitative Disclosures about Market Risk” in our Form 20-F).

 

If we cannot generate sufficient cash flow from operations to make scheduled payments on our debt obligations, we may need to renegotiate the terms of our debt, refinance our debt, obtain additional financing, delay planned capital expenditures or sell assets.

 

If our lenders decline to renegotiate the terms of our debt in these circumstances, the lenders could declare all amounts borrowed and all amounts due to them under the agreements due and payable.

 

3

 

 

We have had a history of losses and our future levels of sales and ability to achieve profitability are unpredictable.

 

As of December 31, 2018 we had an accumulated deficit of $68.8 million. Although we had net income of $990,000 in 2018, $773,000 in 2017, $360,000 in 2016 and $334,000 in 2015, we had a net loss of $433,000 in 2014. In addition, we have had net losses in prior fiscal years. Our ability to maintain and improve future levels of sales and profitability depends on many factors, which include:

 

  delivering products in a timely manners;
     
  successfully implementing our business strategy;
     
  increased demand for existing products; and
     
  controlling costs.

 

There can be no assurance that we will be able to meet our challenges and continue to be profitable in the future or that the level of historic sales will continue in the future.

 

We may be unable to maintain our gross profit margins.

 

Our sales and profitability may vary in any given year, and from quarter to quarter. In order to increase sales or to enter into new markets with new products or due to competition we may find it necessary to decrease prices in order to be competitive. Additionally, our gross profit margin tends to fluctuate mainly due to variety and mix of products and changing suppliers prices. We may not be able to maintain current gross profit margins in the future, which would have a material adverse effect on our business.

 

We depend on one bank for our credit facilities.

 

We rely on the First International Bank of Israel (“Bank Beinleumi”) to provide all of the credit facilities to our subsidiaries. As of December 31, 2018, we had $1.87 million in long term debt to Bank Beinleumi, net of current maturities.

 

Our assets shall subject to a security interest in favor of Bank Beinleumi. Our failure to repay the bank loan, if required, could result in legal action against us, which could require the sale of all of our assets.

 

The repayment of our debt to Bank Beinleumi is secured by a first priority floating charge on all of the present and future assets of the Company and its Israeli Subsidiaries and by a first priority fixed charge on the their - goodwill, unpaid share capital and any insurance entitlements pertaining to assets underlying these charges. In addition, the Company and its Israeli subsidiaries entered into a series of intercompany guarantees in favor of Bank Beinleumi.

 

If we are unable to repay the bank loan when due, the bank could foreclose on our assets in order to recover the amounts due. Any such action might require us to curtail or cease operations (See “Item 5B. Liquidity and Capital Resources” in our Form 20-F).

 

4

 

 

Our debt obligations may hinder our growth and put us at a competitive disadvantage.

 

Our debt obligations require us to use a substantial portion of our operating cash flow to repay the principal and interest on our loans. This reduces funds available to grow and expand our business, limits our ability to pursue business opportunities and makes us more vulnerable to economic and industry downturns. The existence of debt obligations and covenants also limits our ability to obtain additional financing on favorable terms.

 

Due to restrictions in our loan agreements, we may not be able to operate our business as we desire.

 

Our loan agreements contain a number of conditions and limitations on the way in which we can operate our business, including limitations on our ability to raise debt, sell or acquire assets and pay dividends. These limitations may force us to pursue less than optimal business strategies or forgo business arrangements, which could have been financially advantageous to our shareholders and us. Our debt obligations also contain various covenants, which require that we maintain certain financial ratios related to shareholders’ equity and EBITDA and capital to balance sheet ratio. Our failure to comply with the restrictions and covenants contained in our loan agreements could lead to a default under the terms of these agreements (See “Item 5B. Liquidity and Capital Resources” in our Form 20-F).

 

Risks related to our business:

 

We depend on key personnel for the success of our business.

 

Our success depends, to a significant extent, on the continued active participation of our executive officers and other key personnel. In addition, there is significant competition for employees with technical, operational and sales expertise in our industry.

 

In order to succeed we would need to be able to:

 

  retain the executive officers and key personnel who have been involved in the development of our two operating divisions; and
     
  attract and retain highly skilled personnel in various functions of our business.

 

We cannot make assurances that we will be successful in attracting, integrating, motivating and retaining key personnel. If we are unable to retain our key personnel and attract additional qualified personnel as and when needed, our business may be adversely affected.

 

We may be unable to effectively manage our growth and expansion, and as a result, our business results may be adversely affected.

 

Our goal is to grow over the next few years. The management of our growth, if any, will require the continued expansion of our operational and financial control systems, as well as a significant increase in our financial resources and in our delivery and service capabilities. These factors could place a significant strain on our resources.

 

5

 

 

Our growth increases the complexity of our operations, places significant demands on our management and our operational, financial and marketing resources and involves a number of challenges, including:

 

  retaining and motivating key personnel of the acquired businesses;
     
  assimilating different corporate cultures;
     
  preserving the business relationships with existing key customers and suppliers;
     
  maintaining uniform standards, controls, procedures and policies;
     
  introducing joint products, solutions and service offerings; and
     
  having sufficient working capital to finance growth.

 

In addition, our inability to meet our delivery commitments in a timely manner (as a result of unexpected increases in orders, for example) could result in losses of sales, exposure to contractual penalties, costs or expenses, as well as damage to our reputation in the marketplace.

 

Our inability to manage growth effectively could have a material adverse effect on our business, financial condition and results of operations.

 

We may expand our business through acquisitions that could result in diversion of resources and extra expenses. This could disrupt our business and adversely affect our financial condition.

 

In January 2016, we completed the acquisition of the business operations of iDnext Ltd. and its subsidiary Next-Line Ltd. and in June 2019 we completed acquisition of the business operations of Imdecol Ltd. We may expand our services through additional acquisitions. The negotiation of acquisitions, investments or joint ventures, as well as the integration of acquired or jointly developed businesses or technologies, could divert our management’s time and resources. There can be no assurance that we will be able to consume this acquisition or successfully integrate and manage future acquisitions, if they occur.

 

Furthermore, once integrated, acquisitions may not achieve comparable levels of revenues, profitability or productivity which existed prior to the acquisitions or otherwise perform as expected. The occurrence of any of these events could harm our business, financial condition or results of operations.

 

We may not be successful in achieving the potential benefits of the acquisition   of the business operations of Imdecol Ltd.

 

On June 1, 2019, the Company closed the transaction for the acquisition of the business operations of Imdecol Ltd. This acquisition is subject to a variety of risks that could seriously harm our business, financial condition, results of operations, and share price. These risks include, among others:

 

  incurrence of unexpected expenses associated with acquisition and integration of the acquired business into our Company;

 

  difficulties in the assimilation and integration of the acquired operations, personnel, technologies, products, and information systems;

 

  diversion of management’s attention from other business concerns;

 

  contractual disputes;

 

  potential loss of key employees;

 

  incompatible business cultures;

 

  difficulties in implementing and maintaining uniform standards, controls and policies;

 

the impairment of relationships with employees and customers as a result of integration of new personnel; and

 

  potential inability to retain, integrate and motivate key management, marketing, technical sales and customer support personnel.

 

6

 

 

We do not have collateral or credit insurance for all of our customers’ debt, and our allowance for bad debts may increase.

 

Our customers’ debt is derived from sales to customers located primarily in Israel, India, the Far East and Europe. We do not generally require collateral; however, a certain portion of our debt of customers outside of Israel is insured against customer nonpayment through the Israeli Credit Insurance Company Ltd.

 

The balance of allowance for bad debt as of December 31, 2018 amounted to $31,000, which was determined by our management to be sufficient. However, in the event of a global economic slowdown or if a local or global recession reoccurs, we may be required to record additional and significant allowances for bad debts.

 

A substantial part of the sales of our Supply Chain Solutions division is to the Indian market. A decline in our sales to India would have a material adverse effect on our business and financial results.

 

In 2018, revenues derived from the sales of our Supply Chain Solutions division to India accounted to US $4.2 million, or 12.9% of our total revenues. Sales to India could decline due to changes in market demand or for political reasons. Should our sales to India be subject to substantial declines, our business and financial results will be adversely affected.

 

Certain customers of our Supply Chain Solutions division may cancel purchase orders they placed before the delivery.

 

Supply chain programs for the sale of electronic components, including the programs offered by our Supply Chain Solutions division, are designed to accommodate the preference of customers to work with a limited number of suppliers that are able to provide a wide range of electronic components under one order. In the event we are not able to provide all of the components required by a customer, such customer could elect to terminate the entire order before its delivery. In addition, certain of our individual product orders provide a right of termination prior to delivery.

 

In the event substantial orders are so cancelled, there is no assurance that we will be able to sell the pre-purchased inventory at a profit, or at all. This could result in excess and obsolete inventory and could have a material adverse effect on our results of operations.

 

The electronic components provided by our Supply Chain Solutions division need to meet certain industry standards and for some customers we need to be the manufacturers’ authorized distributors.

 

The main business of our Supply Chain Solutions division is the provision of electronic components to the aerospace and defense industry. These components need to be in compliance with Aviation Standard number 9120 which was adopted by the International Aerospace Quality Group. Noncompliance with these standards could limit our sales.

 

In addition, in the face of an increased number of refurbished or non-original components offered in the marketplace, certain customers have begun to insist on only purchasing components directly from authorized distributors of the manufacturers. This could impair our ability to sell components of manufacturers for which we do not serve as authorized dealers and may have a substantial adverse effect on our business.

 

Our products may contain defects that may be costly to correct, delay market acceptance of our products, harm our reputation and expose us to litigation.

 

Despite testing by us, errors may be found in our software products and services. If defects are discovered, we may not be able to successfully correct them in a timely manner, or at all. Defects and failures in our products could result in a loss of, or delay in, market acceptance of our products and could damage our reputation. Although our standard license agreement with our customers contains provisions designed to limit our exposure to potential product liability claims, it is possible that these provisions may not be effective or enforceable under the laws of certain jurisdictions and we could fail to realize revenues and suffer damage to our reputation as a result of, or in defense of, a substantial claim.

 

7

 

 

Our products may infringe on the intellectual property rights of others.

 

Third parties may assert claims that we have violated a patent, trademark, copyright or other proprietary intellectual property right belonging to them. As is characteristic of our industry, there can be no assurance that our products do not or will not infringe on the proprietary rights of third parties, that third parties will not claim infringement by us with respect to patents or other proprietary rights or that we would prevail in any such proceedings. Any infringement claims, whether or not meritorious, could result in costly litigation or arbitration and divert the attention of technical and management personnel. Any adverse outcome in litigation alleging an infringement could require us to develop non-infringing technology or enter into royalty or licensing agreements. If, in such situations, we are unable to obtain licenses on acceptable terms, we may be prevented from selling products that infringe on such intellectual property of a third party. In addition, an unfavorable outcome or settlement regarding one or more of these matters could have a material adverse effect on our business and operating results.

 

The Supply Chain Solutions division engages in a number of business activities governed by U.S. Government Laws and Regulations, which if violated, could subject the Company to civil or criminal fines and penalties.

 

The Supply Chain Solutions division engages in a number of business activities governed by U.S. Government procurement laws and regulations which change frequently, including regulations relating to import-export control and technology transfer restrictions. In addition, the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-corruption laws in other jurisdictions, include anti-bribery provisions. If we, or our sales representatives, fail to comply with these laws and regulations, we could be subject to administrative, civil or criminal liabilities that could have a material adverse effect on our business and results of operations. We may not always be protected in cases of the violation of the FCPA or other anti-corruption laws by our employees or third-parties acting on our behalf and such violations may have a material adverse effect on our reputation, operating results and financial condition.

 

We rely on certain key suppliers .

 

Most of our sales rely on products of certain key suppliers, which we represent on a non-exclusive basis. 37% of our Supply Chain Solutions division purchases in the year 2018 were sourced from five key suppliers and 44% of our Intelligent Robotics and RFID division purchases in the year 2018 were sourced from six other key suppliers (including a software supplier). In the year 2017, 33% of our Supply Chain Solutions division purchases were sourced from five key suppliers and 39% of our Intelligent Robotics and RFID purchases were sourced from six other key suppliers.

 

In the event that any of our key suppliers becomes unable to fulfill our requirements in a timely manner or if we cease our business relationship with any of these suppliers, we may experience an interruption in delivery and a decrease in our business until an alternative supplier can be procured.

 

Future changes in industry standards may have an adverse effect on our business.

 

New industry standards in the aviation and defense industry could cause a portion of our Supply Chain Solutions division’s inventory to become obsolete and unmarketable, which would adversely affect our results of operations.

 

Recent changes in Israeli law in respect of minimum wage and work and rest hours may increase our labor related expenses.

 

In December 2017, the mandatory minimum wage in Israel was raised by approximately 6%, to NIS 5,300. In addition, commencing April 2018, the 43-hour workweek was shortened by one hour (at a pre-determined day), without a reduction in the monthly salary. An employee that continues to work 43 hours per week is now entitled to overtime payment. As a result, we may suffer an increase in our labor costs in Israel, which could adversely affect our profitability.

 

8

 

 

If revenue levels for any quarter fall significantly below our expectations, our results of operations will be adversely affected.

 

Our revenues in any quarter are substantially dependent on orders received and delivered in that quarter. We base our decisions regarding our operating expenses on anticipated revenue trends and our expenses levels are relatively fixed or require some time for adjustment. As a result, revenue levels falling significantly below our expectations will adversely affect our results of operations.

 

The rate of inflation in Israel may negatively impact our costs if it exceeds the rate of devaluation of the NIS against the U.S. dollar. Similarly, the U.S. dollar cost of our operations in Israel will increase to the extent increases in the rate of inflation in Israel are not offset by a devaluation of the NIS in relation to the U.S. dollar.

 

A substantial amount of our revenues is denominated in U.S. dollars (“ U.S. Dollars ” or “ Dollars ”) or is U.S. dollar-linked. However, we incur a significant portion of our expenses, principally salaries and related personnel expenses in Israel and rent for our facilities in Israel, in NIS. As a result, we are exposed to the risk that the rate of inflation in Israel will exceed the rate of devaluation of the NIS in relation to the U.S. dollar or that the timing of this devaluation lags behind inflation in Israel. In any such event, the U.S. dollar cost of our operations in Israel will increase and our U.S. dollar-measured results of operations will be adversely affected.

 

Similarly, we are exposed to the risk that the NIS, after adjustment for inflation in Israel, will appreciate in relation to the U.S. dollar. In that event, the dollar-measured costs of our operations in Israel will increase and our dollar-measured results of operations will be adversely affected. In 2018, the NIS depreciated against the dollar by approximately 8.1%, while in 2017 the NIS appreciated against the dollar by 9.8%. In 2016 the NIS appreciated against the dollar by 1.5%, and in 2015 the NIS depreciated by approximately 0.3% against the U.S. dollar. In the years ended December 31, 2018 and 2017, the inflation rate in Israel was 0.8% and 0.4%, respectively. In 2016 and 2015 the annual deflation was 0.2% and 1%, respectively. Therefore, the U.S. dollar cost of our Israeli operations decreased in 2018 and 2015, and increased in 2017 and 2016. We cannot predict any future trends in the rate of inflation in Israel and whether the NIS will appreciate against the U.S. dollar or vice versa. Any increase in the rate of inflation in Israel, unless the increase is offset on a timely basis by a devaluation of the NIS in relation to the U.S. dollar, will increase our labor and other costs, which will increase the U.S. dollar cost of our operations in Israel and harm our results of operations (see “Item 5A. Results of Operation - Impact of Inflation and Currency Fluctuations” in our Form 20-F).

 

If we are unsuccessful in introducing new products, we may be unable to expand our business.

 

The market for some of our products is characterized by rapidly changing technology and evolving industry standards. The introduction of products embodying new technology and the emergence of new industry standards can render existing products obsolete and unmarketable and can exert price pressures on existing products.

 

Our ability to anticipate changes in technology and industry standards and successfully market new and enhanced products as well as additional applications for existing products, in each case on a timely basis, will be critical in our ability to grow and remain competitive. If we are unable, for technological or other reasons, to market products that are competitive in technology and price and responsive to customer needs, our business will be materially adversely affected.

 

9

 

 

Disruptions to our IT systems due to system failures or cyber security attacks may impact our operations, result in sensitive customer information being compromised, which would negatively materially affect our reputation and materially harm our business.

 

Our servers and equipment may be subject to computer viruses, break-ins, and similar disruptions from unauthorized tampering with computer systems. Our systems have been, and are expected to continue to be, the target of malware and other cyber-attacks. Although we have invested in measures to reduce these risks, there can be no assurance that our current information technology (IT) systems are fully protected against third-party intrusions, viruses, hacker attacks, information or data theft or other similar threats. A cyber-attack that bypasses our IT security systems causing an IT security breach may lead to a material disruption of our IT business systems and/or the loss of business information. A cyber-attack on our systems or networks that impairs our IT systems could disrupt our business operations and our ability to sell our products. Any such event could have a material adverse effect on our business. To the extent that such disruptions or uncertainties result in delays or cancellations of customer orders or shipment of our products, or in theft, destruction, loss, misappropriation or release of our confidential information or our intellectual property, our business, financial condition, results of operations and prospects could be materially adversely affected.

 

We have significant sales worldwide and could encounter problems if conditions change in the places where we market products.

 

We have sold and intend to continue to sell products in overseas markets, including in India, the Far East, America and Europe. A number of risks are inherent in engaging in international transactions, including:

 

  possible problems in collecting receivables;
     
  the imposition of governmental controls, or export license requirements;
     
  political and economic instability in foreign companies;
     
  foreign currency exchange rate risk;
     
  trade restrictions or changes in tariffs being imposed; and
     
  laws and legal issues concerning foreign countries.

 

Should we encounter such difficulties in conducting our international operations, they may adversely affect our business condition and results of operations.

 

Unfavorable global economic conditions could have a material adverse effect on our business, operating results and financial condition.

 

A financial and economic downturn in Israel, India or in one or more of our overseas markets may cause revenues of our customers to decrease. This may result in reductions in sales of products and services in some markets, longer sales cycles, slower adoption of new technologies and increased price competition. In addition, weakness in the end-user market could negatively affect the cash flow of our customers who could, in turn, delay paying their obligations to us. This could increase our credit risk exposure and cause delays in our recognition of revenues on future sales to these customers.

 

We may be obligated to indemnify our directors and officers .

 

The Company has agreements with its directors and senior officers which provide, subject to Israeli law, indemnification by the Company for its directors and senior officers for: (a) monetary liability imposed upon a director or officer in favor of a third party by a judgment, including a settlement or an arbitral award confirmed by the court, as a result of an act or omission of such person in his or her capacity as a director or officer of the Company, (b) reasonable litigation expenses, including attorney’s fees, incurred by a director or officer (A) pursuant to an investigation or a proceeding commenced against him or her by a competent authority, provided that (i) it was terminated without the filing of an indictment and without having a monetary charge imposed them in lieu of criminal proceedings (as such terms are defined in the Israeli Companies Law; or (ii) it was terminated without the filing of an indictment but with a monetary charge imposed on him or her in lieu of criminal proceedings for a crime that does not require proof of criminal intent; (B) or in connection with a financial sanction, as a result of an act or omission of such person in its capacity as a director or officer of the Company, (c) reasonable litigation expenses, including attorney’s fees, incurred by a director or officer or imposed on him or her by a court, in a proceeding brought against him or her by or on behalf of the Company or by a third party, or in a criminal action in which he or she was acquitted, or in a criminal action which does not require criminal intent in which he was convicted, in each case relating to acts or omissions of such person in its capacity as a director or officer of the Company, (d) expenses, including reasonable litigation expenses and legal fees, incurred by such a director or officer as a result of a proceeding instituted against him in relation to (A) infringements that may result in imposition of financial sanction pursuant to the provisions of Chapter H'3 under the Israeli Securities Law 5728 – 1968 (the “Israeli Securities Law”) or (B) administrative infringements pursuant to the provisions of Chapter H'4 under the Israeli Securities Law or (C) infringements pursuant to the provisions of Chapter I'1 under the Israeli Securities Law; and (e) payments to an injured party of infringement under Section 52ND(a)(1)(a) of the Israeli Securities Law. Payments pursuant to such indemnification obligation may materially adversely affect our financial condition.

 

10

 

 

There can be no assurance that we will not be classified as a passive foreign investment company (a “PFIC”).

 

Based on our current and projected income, assets and activities, we do not believe that, at this time, BOS is a passive foreign investment company for U.S. federal income tax purposes, but there can be no assurance that we will not be classified as such in the future. Such classification may have materially adverse tax consequences for our U.S. shareholders. One method of avoiding such tax consequences is by making a “qualified electing fund” election for the first taxable year in which the Company is a PFIC. However, such an election is conditioned upon our furnishing our U.S. shareholders annually with certain tax information. We do not presently prepare or provide such information, and such information may not be available to our U.S. shareholders if we are subsequently determined to be a PFIC. You are advised to consult with your own tax advisor regarding the particular tax consequences related to the ownership and disposition of our Ordinary Shares under your own particular factual circumstances.

 

A decline in the value of our market capitalization or other factors could require us to write-down the value of our goodwill, which could have a material adverse effect on our results of operations.

 

Our balance sheet contains a significant amount of goodwill and other amortizable intangible assets in long-term assets, totaling about $4.76 million at December 31, 2018. We review goodwill annually for impairment, or more frequently when indications for potential impairment exist. We review other amortizable intangible assets for impairment when indicators for impairment exist. The volatility of our share price can cause significant changes to our market capitalization.

 

If our market capitalization experiences a significant decline and is below the value of our Shareholders’ equity, if the carrying amount of a reporting unit exceeds its fair value or if any other quantitative or qualitative indication of impairment of goodwill arises in the future, we may be required to record impairment charges for our goodwill. Any such write-downs, if required, could result in a significant non-cash expense on our income statement, which could have a material adverse effect on our results of operations.

 

There are substantial risks associated with the YA II Standby Equity Distribution Agreement, which could contribute to the decline of our share price and have a dilutive impact on our existing shareholders.

 

The sale of our Ordinary Shares to YA II PN, Ltd. (or YA II) (formerly YA Global Master SPV Ltd.), pursuant to the Standby Equity Distribution Agreement, dated as May 8, 2017, (the “ 2017 SEDA ”), (see “Item 5B – Liquidity and Capital Resources” in our Form 20-F) will have a dilutive impact on our shareholders. Under the 2017 SEDA, we have the right to sell, over a period of up to 4 years, Ordinary Shares to YA II for up to a total purchase price of $2,000,000, out of which $1,100,000 remain available as of June 30, 2019. YA II may resell some, if not all of the shares we issue to it under the 2017 SEDA and such sales could cause the market price of our Ordinary Shares to decline.

 

Our business could be impacted as a result of actions by activist shareholders or others.

 

We may be subject, from time to time, to legal and business challenges in the operation of our company due to actions instituted by activist shareholders or others. Responding to such actions could be costly and time-consuming, may not align with our business strategies and could divert the attention of our Board of Directors and senior management from the pursuit of our business strategies. Perceived uncertainties as to our future direction as a result of shareholder activism may lead to the perception of a change in the direction of the business or other instability and may affect our relationships with vendors, customers, prospective and current employees and others.

 

11

 

 

We may fail to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, which could have a material adverse effect on our operating results, investor confidence in our reported financial information and the market price of our Ordinary Shares.

 

Our efforts to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, governing internal control and procedures for financial reporting have resulted in increased general and administrative expenses and a diversion of management time and attention. We expect these efforts to require the continued commitment of significant resources. We may identify material weaknesses or significant deficiencies in our assessments of our internal control over financial reporting. Failure to maintain effective internal control over financial reporting could result in investigations or sanctions by regulatory authorities and could have a material adverse effect on our operating results, investor confidence in our reported financial information and the market price of our Ordinary Shares.

 

If our employees commit fraud or engage in other misconduct, including noncompliance with regulatory standards and requirements or insider trading, our business may experience material adverse consequences.

 

During the course of our operations, our directors, executives and employees may have access to material, nonpublic information regarding our business, our results of operations or potential transactions we are considering. Despite the adoption of an Insider Trading Policy, we may not be able to prevent a director, executive or employee from trading in our ordinary shares on the basis of, or while having access to, such information.

 

In addition, while we have designed and operate an internal control system, we cannot provide absolute assurance that instances of fraud, if any, shall be prevented or detected. 

 

If a director, an executive or an employee was to be investigated, or an action was to be brought against him or her for insider trading or fraud, it could have a negative impact on our reputation and our share price. Such a claim, with or without merit, could also result in substantial expenditures of time and money and divert attention of our management team from other tasks important to the success of our operations.

 

12

 

 

Risks related to our Ordinary Shares:

 

Our share price has been and may continue to be volatile, which could result in substantial losses for individual shareholders.

 

The market price of our Ordinary Shares has been and may continue to be highly volatile and subject to wide fluctuations. From January 1, 2018 through August 5, 2019, the daily closing price of our Ordinary Shares in NASDAQ has ranged from $1.93 to $3.94 per share. We believe that these fluctuations have been in response to a number of factors including the following, some of which are beyond our control:

 

  variations between actual results and projections;
     
  the limited trading volume in our stock;
     
  changes in our bank debts; and
     
  Nasdaq Capital Market Listing Standards non-compliance notices;

 

In addition, stock markets in general have, from time to time, experienced extreme price and volume fluctuations. This volatility is often unrelated or disproportionate to the operating performance of the affected companies. These broad market fluctuations may adversely affect the market price of our Ordinary Shares, regardless of our actual operating performance.

 

The Company’s shares may be delisted from the NASDAQ Capital Market if it does not meet NASDAQ’s continued listing requirements.

 

Over the years, the Company has received several notices from the NASDAQ Stock Market advising it of the non-compliance of its shares with continued listing requirements on the NASDAQ Capital Market.

 

 There can be no assurance that the Company will continue to qualify for listing on the Nasdaq Capital Market. If the Company’s Ordinary Shares are delisted from the Nasdaq Capital Market, trading in its Ordinary Shares could be conducted on the over-the-counter market. In addition, if the Company’s Ordinary Shares were delisted from the Nasdaq Capital Market, it would be subject to the so-called penny stock rules that impose restrictive sales practice requirements on broker-dealers who sell those securities. Consequently, de-listing, if it occurred, could affect the ability of our shareholders to sell their Ordinary Shares in the secondary market. The restrictions applicable to shares that are de-listed, as well as the lack of liquidity for shares that are traded on an electronic bulletin board, may adversely affect the market price of such shares.

 

Risks related to our location in Israel:

 

Political, economic, and security conditions in Israel affect our operations and may limit our ability to produce and sell products or provide our services.

 

We are incorporated under the laws of the State of Israel, where we also maintain our headquarters and our principal research and development and sales and marketing facilities. As a result, political, economic and military conditions affecting Israel directly influence us.

 

Since its establishment in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries. In recent years, these have included hostilities between Israel and Hezbollah in Lebanon, and Israel and Hamas in the Gaza Strip, both of which resulted in rockets being fired into Israel causing casualties and disruption of economic activities. Recent political uprisings and conflicts in various countries in the Middle East, including Egypt and Syria, are affecting the political stability of those countries. Any armed conflicts, terrorist activities, political instability or hostilities in the region or that involve Israel or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect our business, financial condition and results of operations and could make it more difficult for us to raise capital. In addition, Israel faces threats from more distant neighbors, in particular, Iran that has threatened to attack Israel. Iran is also believed to have a strong influence among extremist groups in areas that neighbor Israel, such as Hamas in Gaza and Hezbollah in Lebanon. Additionally, the Islamic State of Iraq and Syria (ISIS), a violent jihadist group, is involved in hostilities in Iraq and Syria and its stated purpose is to take control of the Middle East, including Israel.

 

13

 

 

Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government has in the past covered the reinstatement value of certain damages that were caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our operations.

 

To date, these matters have not had any material effect on our business and results of operations; however, the regional security situation and worldwide perceptions of it are outside our control and there can be no assurance that these matters will not negatively affect us in the future.

 

Furthermore, several countries and companies restrict business with Israel and Israeli companies. Restrictive laws or policies directed towards Israel or Israeli businesses may have an adverse impact on our operations, our financial results or the expansion of our business.

 

A number of our key personnel in Israel have standing obligations to perform periodic reserve duty in the Israel Defense Forces and are subject to be called up for active military duty at any time. If our key personnel are absent from our business for a significant period of time, we may experience disruptions in our business that could affect the development, sales or technical support of our products. As a result, we might not be able to compete in the market and our results of operations could be harmed.

 

The anti-takeover effects of Israeli laws may delay or deter a change of control of the Company.

 

Provisions of Israeli law may delay, prevent or make undesirable a merger or an acquisition of all or a significant portion of our shares or assets. The Israeli Companies Law regulates acquisitions of shares through tender offers and mergers, requires special approvals for transactions involving significant shareholders and regulates other matters that may be relevant to these types of transactions. These provisions of Israeli law could have the effect of delaying or preventing a change in control and may make it more difficult for a third party to acquire us, even if doing so would be beneficial to our shareholders. These provisions may limit the price that investors may be willing to pay in the future for our Ordinary Shares. Furthermore, Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders.

 

These laws may have the effect of delaying or deterring a change in control of the Company, thereby limiting the opportunity for shareholders to receive a premium for their shares and possibly affecting the price that some investors are willing to pay for the Company’s securities.

 

All of our directors and officers are non-U.S. residents and enforceability of civil liabilities against them is uncertain.

 

All of our directors and officers reside outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.

 

Your rights and responsibilities as our shareholder will be governed by Israeli law, which differ in some respects from the rights and responsibilities of shareholders of United States corporations.

 

Since we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our articles of association and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in United States-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith towards the company and other shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment to the company’s articles of association, an increase of the company’s authorized share capital, a merger and approval of related party transactions that require shareholder approval. In addition, a shareholder who knows that it possesses the power to determine the outcome of a shareholders’ vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness towards the company. These provisions may be interpreted to impose additional obligations and liabilities on our shareholders that are not typically imposed on shareholders of U.S. corporations.

 

14

 

 

As a foreign private issuer whose shares are listed on the Nasdaq Capital Market, we follow and may in the future elect to follow certain home country corporate governance practices instead of certain Nasdaq requirements.

 

We are a foreign private issuer as such term is defined under U.S. federal securities laws. As a foreign private issuer, we have elected to follow certain home country corporate governance practices, instead of certain requirements of the Marketplace Rules of the Nasdaq Capital Market, or the Nasdaq Marketplace Rules. We may in the future elect to follow Israeli corporate governance practices with regard to, among other things, the composition of our board of directors (“ Board of Directors ”), compensation of officers, director nomination procedures and quorum requirements at shareholders’ meetings. In addition, we may elect to follow Israeli corporate governance practices instead of the Nasdaq requirements to obtain shareholder approval for certain dilutive events (such as for the establishment or amendment of certain equity-based compensation plans, issuances that will result in a change of control of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company and certain acquisitions of the stock or assets of another company). Accordingly, our shareholders may not be afforded the same protection as provided under Nasdaq’s corporate governance rules. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the Nasdaq Capital Market may provide less protection than is accorded to investors of domestic issuers. See “Item 16G – Corporate Governance” in our Form 20-F.

 

If we were to lose our foreign private issuer status under U.S. federal securities laws, we would incur additional expenses associated with compliance with the U.S. securities laws applicable to U.S. domestic issuers.

 

As a foreign private issuer, we are exempt from the rules and regulations under the Securities and Exchange Act of 1934, as amended (the “ Exchange Act ”), related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the Securities and Exchange Commission as frequently or as promptly as domestic companies whose securities are registered under the Exchange Act.

 

The regulatory and compliance costs to us under U.S. securities laws, if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer, may be significantly higher than the cost we currently incur as a foreign private issuer.

 

15

 

 

As a public company in the United States, we incur significant accounting, legal and other expenses as a result of listing our Ordinary Shares on the Nasdaq Capital Market, and we may need to devote substantial resources to address new compliance initiatives and reporting requirements.

 

As a public company in the United States, the Exchange Act requires that we file periodic reports with respect to our business and financial condition and maintain effective disclosure controls and procedures and internal control over financial reporting. In addition, subsequent rules implemented by the SEC and the NASDAQ Stock Market may also impose various additional requirements on public companies. As a result, we incur significant accounting, legal and other expenses as a result of listing our Ordinary Shares on the Nasdaq Capital Market. These include costs associated with corporate governance requirements of the SEC and the Marketplace Rules of Nasdaq, as well as requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002. Any future changes in the laws and regulations affecting public companies in the United States and Israel, will result in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our board committees or as executive officers.

 

FORWARD-LOOKING STATEMENTS

 

This prospectus, including the information incorporated by reference into this prospectus, contains, and any prospectus supplement may contain, forward-looking statements within the meaning of the federal securities laws. These statements address, among other things: our strategy; the anticipated development of our products; the results of completed acquisitions and our ability to make future acquisitions; our projected capital expenditures and liquidity; our development of additional revenue sources; our development and expansion of relationships; the market acceptance of our products; our technological advancement; our compliance with regulatory requirements; and our ability to operate due to political, economic and security conditions. Actual results could differ materially from those anticipated, expressed or implied in these forward-looking statements as a result of various factors, including all the risks discussed above and elsewhere in this prospectus.

 

We urge you to consider that statements that use the terms “believe”, “do not believe”, “expect”, “plan”, “intend”, “estimate”, “anticipate”, “projections”, “forecast”, “may”, “continue”, “should”, “predict”, “potential” or the negative of these terms or similar expressions are intended to identify forward-looking statements. These statements reflect our current views with respect to future events. These statements are based on beliefs and assumptions and are subject to risks and uncertainties. These risk factors and uncertainties include, amongst others, the dependency of sales being generated from one or few major customers, the uncertainty of BOS being able to maintain current gross profit margins, inability to keep up or ahead of technology and to succeed in a highly competitive industry, inability to maintain marketing and distribution arrangements and to expand our overseas markets, uncertainty with respect to the prospects of legal claims against BOS, the effect of exchange rate fluctuations, general worldwide economic conditions and continued availability of financing for working capital purposes and to refinance outstanding indebtedness; and additional risks and uncertainties set forth in this prospectus, including under the heading “Risk Factors.” Therefore, we caution you to consider the matters described under the heading “Risk Factors” and certain other matters discussed in this prospectus, the documents incorporated by reference in this prospectus and other publicly available resources. Except as required by applicable law, including the federal securities laws of the United States, we do not intend to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Market data and forecasts used in this prospectus have been obtained from independent industry sources that we believe to be reliable. We have not independently verified the data obtained from these sources and we cannot assure you of the accuracy or completeness of the data. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and additional uncertainties accompanying any estimates of future market size.

  

16

 

 

CAPITALIZATION AND INDEBTEDNESS

 

The table below sets forth our condensed consolidated current liabilities and capitalization at December 31, 2018 on an actual basis. This table was prepared in accordance with the U.S. Generally Accepted Accounting Principles.

 

Consolidated Capitalization (in US thousands of dollars)

  

    December 31,
2018
 
       
Short term debt        
Secured   $ 467  
Unsecured   $ 5,965  
Total short term debt   $ 6,432  
         
Long term debt        
Secured   $ 1,867  
Unsecured   $ 301  
Total long term debt   $ 2,168  
         
Shareholders equity        
Share capital: Ordinary Shares        
Issued 3,236,319 Ordinary Shares nominal value NIS 80.00 per share   $ 75,317  
Additional paid-in Capital   $ 5,369  
Accumulated other comprehensive loss   $ (333 )
Accumulated deficit   $ (68,842 )
Total shareholders' equity   $ 11,511  

 

The Company's operations are financed through cash flows from operating activities, from long term loans and from equity investments. (See “Item 5B. Liquidity and Capital Resources” in our Form 20-F).

 

USE OF PROCEEDS

 

We will not receive any proceeds from the sale of shares by the Selling Shareholders. All net proceeds from the sale of the Ordinary Shares covered by this prospectus will be paid to the Selling Shareholders.  We will, however, receive proceeds upon exercise of the Warrants and the RHK Warrants issued to the Selling Shareholders, which we anticipate will be used for working capital and general corporate purposes.

  

17

 

 

SELLING SHAREHOLDERS

   

On May 16, 2019 we entered into and closed the Agreement with the Selling Shareholders for the sale of 400,000 Ordinary Shares at a price of $2.50 per share, resulting in gross proceeds of $1 million.

 

In addition, we issued, to the Selling Shareholders 240,000 warrants with an exercise price of $3.30 per Ordinary Share. The Warrants shall be exercisable for 3.5 years and shall be subject to a 3 vesting period as follows: one third of the warrants shall vest annually (upon the lapse of 12 months, 24 months and 36 months from issuance), provided that on the applicable vesting date the investor did not sell any of the Ordinary Shares purchased under the Agreement. Vesting of all of the Warrants shall be accelerated in the event that any one or more shareholders acting together acquire a block of 40% of the Company’s issued and outstanding share capital.

 

We have paid to RHK Capital (a unit of Advisory Group Equity Services, Ltd. a sales commission of $40,000, and agreed to issue to RHK Capital 60,000 warrants with an exercise price of $3.30 per ordinary share.

 

The table below sets forth certain information concerning the number of ordinary shares owned by each of the Selling Shareholders as of August 8, 2019 and the number of ordinary shares that may be offered from time to time by the Selling Shareholders under this prospectus. Because each of the Selling Shareholder may offer all or some portion of the ordinary shares, BOS has assumed for the purposes of the table below that each of the Selling Shareholder will sell all of the ordinary shares offered. None of the Selling Shareholders has served in any position, or office with the Company, or had any other material relationship with the Company or any of its predecessors or affiliates within the last three years.  

 

    Shares Owned or Underlying Securities Prior to Offering     Shares Being     Shares Beneficially Owned After the Offering (2)  
    Number     Percent (3)     Offered (1)     Number      Percent (3)  
Premier Financial Concepts LLC (4)     202,000       4.7 %     192,000       10,000       0.2 %
Rodney Speight     32,000       0.7 %     32,000       0       0.0 %
Ralph J. Fratus Jr.     64,000       1.5 %     64,000       0       0.0 %
Michele Roverto Manago     32,000       0.7 %     32,000       0       0.0 %
The John C. & Desiree A. Coats Trust dated 03/29/04 (5)     32,000       0.7 %     32,000       0       0.0 %
The Walter and Laura Whetstine Revocable Living Trust dated 10/12/2010 (6)     32,000       0.7 %     32,000       0       0.0 %
Woodman Revocable Trust dated 08/12/12 (7)     32,000       0.7 %     32,000       0       0.0 %
Todd M. Felte (8)     84,000       1.9 %     77,000       7,000       0.2 %
Kristi Dorman     33,500       0.8 %     32,000       1,500       0.0 %
Dean Amato     64,000       1.5 %     64,000       0       0.0 %
Dana W. Amato     186,899       4.4 %     96,000       90,899       2.1 %
Advisory Group Equity Services (9)     1,500       0.0 %     1,500       0       0.0 %
Bruce Ryan (10)     6,750       0.2 %     6,750       0       0.0 %
Richard H. Kreger (10)     6,750       0.2 %     6,750       0       0.0 %

  

(1) Number of shares being offered includes the maximum number of shares that may be received by the each of the Selling Shareholders upon the full exercise of warrants they hold into ordinary shares.
(2) It is assumed with respect to each Selling Shareholder that all of the shares being offered under this Registration Statement have been sold.
(3) Calculated based upon 4,258,481 ordinary shares outstanding as of August 8, 2019.
(4) Mr. James Orders may be deemed to have sole voting and dispositive power with respect to the shares held by Premier Financial Concepts LLC.
(5) Mr. John C. Coats may be deemed to have sole voting and dispositive power with respect to the shares held by The John C. & Desiree A. Coats Trust dated 03/29/04
(6) Mrs Laura Whetstine may be deemed to have sole voting and dispositive power with respect to the shares held by The Walter and Laura Whetstine Revocable Living Trust dated 10/12/2010
(7) Mr. Garett Hatch may be deemed to have sole voting and dispositive power with respect to the shares held by Woodman Revocable Trust dated 08/12/12
(8) Includes 45,000 warrants issued to Mr. Felte as an affiliate of RHK Capital.
(9) An affiliate of RHK Capital. Mr. William H. McCance may be deemed to have sole voting and dispositive power with respect to the shares held by Advisory Group Equity Services.

   

18

 

 

PLAN OF DISTRIBUTION

 

Each of the Selling Shareholders and any of their respective pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their Ordinary Shares on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. Each of the Selling Shareholders may use any one or more of the following methods when selling shares:

 

  ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
     
  block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
     
  purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
     
  an exchange distribution in accordance with the rules of the applicable exchange;
     
  privately negotiated transactions;
     
  “at the market” or through market makers or into an existing market for the shares;
     
  broker-dealers may agree with the selling shareholders to sell a specified number of such shares at a stipulated price per share;
     
  through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
     
  a combination of any such methods of sale; or
     
  any other method permitted pursuant to applicable law.

 

Each of the Selling Shareholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.

 

19

 

 

Broker-dealers engaged by the Selling Shareholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Shareholder (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission, in compliance with the rules of FINRA.

 

In connection with the sale of the Ordinary Shares or interests therein, the Selling Shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Ordinary Shares in the course of hedging the positions they assume. The Selling Shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

  

To the best of our knowledge, no other underwriter or person has been engaged to facilitate the sale of Ordinary Shares in this offering.

 

The SEC may take the view that, under certain circumstances, any broker-dealers or agents that participate in the distribution of the Ordinary Shares may be deemed to be “underwriters” within the meaning of the Securities Act. Commissions, discounts or concessions received by any such broker-dealer or agent may be deemed to be underwriting commissions under the Securities Act.

 

We have agreed to keep this prospectus effective until the date which is the earlier of: (i) the date when all of the Ordinary Shares registered pursuant hereunder (the “ Resale Shares ”) have been sold; and (ii) 4 years from the date of the Agreement. The Resale Shares will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the Resale Shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

 

Expenses, Indemnification

 

We will bear all expenses related to the registration of this offering but will not pay for any commissions, fees or discounts, if any. We have agreed to indemnify the Selling Shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

 

Supplements

 

In the event of a material change in the plan of distribution disclosed in this prospectus, the Selling Shareholders will not be able to effect transactions in the shares pursuant to this prospectus until such time as a post-effective amendment to the registration statement is filed with, and declared effective by, the SEC.

 

Regulation M

 

We have informed the Selling Shareholders that Regulation M promulgated under the Exchange Act may be applicable to it with respect to any purchase or sale of our Ordinary Shares. In general, Rule 102 under Regulation M prohibits any person connected with a distribution of our Ordinary Shares from directly or indirectly bidding for, or purchasing for any account in which it has a beneficial interest, any of the shares or any right to purchase the shares, for a period of one business day before and after completion of its participation in the distribution.

 

20

 

  

During any distribution period, Regulation M prohibits The Selling Shareholders and any other persons engaged in the distribution from engaging in any stabilizing bid or purchasing our Ordinary Shares except for the purpose of preventing or retarding a decline in the open market price of the Ordinary Shares. None of these persons may affect any stabilizing transaction to facilitate any offering at the market.

 

We have also advised the Selling Shareholders that they should be aware that the anti-manipulation provisions of Regulation M under the Exchange Act will apply to its purchases and sales of Ordinary Shares, and that there are restrictions on market-making activities by persons engaged in the distribution of the shares. Under Regulation M, each Selling Shareholder or its agents may not bid for, purchase, or attempt to induce any person to bid for or purchase, shares of our Ordinary Shares while it is distributing shares covered by this prospectus. Regulation M may prohibit the Selling Shareholders from covering short sales by purchasing shares while the distribution is taking place. We have advised each Selling Shareholder that it should consult with its own legal counsel to ensure compliance with Regulation M.

 

DESCRIPTION OF ORDINARY SHARES

 

The following is a summary description of our Ordinary Shares under our Articles of Association.

 

Dividend and Liquidation Rights .

 

All holders of paid-up Ordinary Shares of the Company have an equal right to participate in a distribution of (i) dividends, whether by cash or by bonus shares; (ii) Company assets; and (iii) the Company’s surplus assets upon winding up, all pro rata to the nominal value of the shares held by them.

 

The Board of Directors may issue shares and other securities, which are convertible or exercisable into shares, up to the limit of the Company’s authorized share capital.

 

The Company’s Board of Directors is authorized to decide upon the distribution of dividends or bonus shares.

 

We have never declared or paid any cash dividend on our ordinary shares. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. Any further determination to pay dividends on our ordinary shares will be at the discretion of our Board of Directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions, and other factors that our Board of Directors considers relevant.

 

Voting, Shareholders’ Meetings, Notices and Resolutions .

 

Holders of paid-up Ordinary Shares have one vote for each share held on all matters submitted to a vote of shareholders. Such voting rights may be affected in the future by the grant of any special voting rights to the holders of a class of shares with preferential rights.

 

The quorum required for a general meeting of shareholders (whether annual or special) consists of at least two shareholders present in person or by proxy/voting instrument and holding, or representing, at least 33⅓% of the voting rights of the issued share capital. A meeting adjourned for lack of quorum shall be postponed by one week, to the same day, time and place, or to a later time if stated in the invitation to the meeting or in the notice of the meeting. The quorum for the commencement of the adjourned meeting shall be any number of participants.

 

Unless otherwise determined by the Israeli Companies Law or the Company’s Articles of Association, a resolution requires approval by the holders of a majority of the shares represented at the meeting, in person or by proxy, and voting thereon.

 

The Israeli Companies Law requires that certain transactions, actions and arrangements be approved by shareholders, including (i) arrangements with a director and/or the CEO as to the terms of his office and compensation and arrangements for insurance, exemption and indemnity of directors; (ii) certain Extraordinary Transactions (as defined in the Israeli Companies Law) of the Company with its controlling shareholders or any Extraordinary Transaction in which a controlling shareholder has a personal interest; and (iii) any action or Extraordinary Transaction in which the majority of the members of the Board of Directors have a personal interest.

 

21

 

 

Each shareholder of record is entitled to receive at least 21 days prior notice of shareholders’ meetings. The accidental omission to give notice of a meeting to any member, or the non-receipt of notice sent to such member, shall not invalidate the proceedings at such meeting. For the purposes of determining the shareholders entitled to notice and to vote, the Board of Directors may fix a record date subject to the provisions of the law. Currently, Israeli law provides that the record date not be any earlier than 40 days prior to the meeting.

 

Transfer of Shares .

 

Subject to applicable securities laws, fully paid Ordinary Shares may be transferred freely. The transfer of Ordinary Shares not fully paid up requires the approval of the Board of Directors.

 

Modification of Class Rights .

 

Subject to the provisions of any law, the rights attached to any class (unless otherwise provided by the terms of issue of such class), such as voting, rights to dividends and other similar rights, may be altered after a resolution is passed by the Company, with the approval of a resolution passed by a majority of the voting power present by person or proxy and voting hereon at a general meeting of the holders of the shares of such class or the written agreement of all the class holders. The rights vested in the holders of shares of a particular class that were issued with special rights shall not be deemed to have been altered by the creation or issue of further shares ranking equally with them, unless otherwise provided in such shares’ issue terms.

 

Election of Directors .

 

Pursuant to the Company’s Articles of Association, the number of directors in the Company shall be determined from time to time by the annual general meeting of shareholders, provided that it shall neither be less than four nor more than eleven. The Company’s directors are elected by the shareholders at general shareholder meeting. The Ordinary Shares do not have cumulative voting rights for the election of directors. The holders of Ordinary Shares conferring more than 50% of the voting power present by person or by proxy at the shareholder meeting, have the power to elect the directors. The directors elected shall hold office until the next annual shareholder meeting, or sooner if they cease to hold office pursuant to the provisions of the Company’s Articles. In addition, the Board of Directors may appoint a director (to fill a vacancy or otherwise) between shareholder meetings, and such appointment shall be valid until the next annual meeting or until such appointee ceases to hold office pursuant to the provisions of the Company’s Articles.

 

Regulation 5D of the Israeli Companies Regulations (Reliefs for Public Companies whose Shares are Listed on a Stock Exchange Outside of Israel), 2000 provides that a public company with securities listed on the Nasdaq Capital Market and has no controlling shareholder, may elect to be exempt from the requirements under the Israeli Companies Law, to appoint external directors or regarding the composition of the audit and compensation committees. The exemption is available, provided the company satisfies the requirements applicable to domestic US issuers in these matters.

 

On October 16, 2017 our Board of Directors determined that we comply with the requirements applicable to US issuers listed on Nasdaq in connection with a majority of independent directors on the Board of Directors and with the composition of each of the audit committee and compensation committee, and determined to adopt the exemption. Consequently, the Company’s Board of Directors, audit and compensation committees no longer include external directors.

   

22

 

  

OFFERING EXPENSES

 

The following is a statement of expenses in connection with the distribution of the securities registered. All amounts shown are estimates except for the SEC registration fee. The estimates do not include expenses related to offerings of particular securities.

 

SEC registration fees   $ 259.60  
Legal fees, Audit Fees and expenses   $ 10,000.00  
Miscellaneous expenses   $ 2,000.00  
         
TOTAL   $ 12,259.60  

 

VALIDITY OF SECURITIES

 

The validity of the Ordinary Shares offered in this prospectus, will be passed upon for us by Gornitzky & Co., our Israeli counsel. Certain other legal matters relating to United States law will be passed upon for us by Phillips Nizer LLP, New York, New York.

 

EXPERTS

 

Financial statements of B.O.S. Better Online Solutions Ltd for the years 2017 and 2018, incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the report of Fahn Kanne & Co. Grant Thornton Israel, an independent registered public accounting firm, upon the authority of said firm as experts in accounting and auditing.

 

Financial statements of B.O.S. Better Online Solutions Ltd for the year 2016, incorporated by reference in this prospectus and elsewhere in the registration statement, have been so incorporated by reference in reliance upon the report of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, an independent registered public accounting firm, upon the authority of said firm as experts in accounting and auditing.

 

Financial statements of Imdecol Ltd., incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the report of Alan Moldof, an independent accountant, upon his authority as an expert in accounting and auditing.

   

WHERE YOU CAN FIND MORE INFORMATION

 

We have filed with the SEC a registration statement on Form F-3 under the Securities Act, with respect to the securities offered by this prospectus. However, as is permitted by the rules and regulations of the SEC, this prospectus, which is part of our registration statement on Form F-3, omits certain non-material information, exhibits, schedules and undertakings set forth in the registration statement. For further information about us, and the securities offered by this prospectus, please refer to the registration statement.

 

We are subject to the reporting requirements of the Exchange Act that are applicable to a foreign private issuer. In accordance with the Exchange Act, we file reports, including annual reports on Form 20-F by April 30 of each year.

  

23

 

  

The registration statement on Form F-3 of which this prospectus forms a part, including the exhibits and schedules thereto, and reports and other information filed by us with the SEC are available at the SEC’s website at at http:// www.sec.gov

 

As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders and our officers, directors and principal shareholders are exempt from the “short-swing profits” reporting and liability provisions contained in Section 16 of the Exchange Act and related Exchange Act rules.

 

We maintain a corporate website at www.boscorporate.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website in this prospectus solely as an inactive textual reference.

 

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

 

The SEC allows us to “incorporate by reference” into this prospectus the information we file with or submit to it. This means that we can disclose important information to you by referring to those documents. Each document incorporated by reference is current only as of the date of such document, and the incorporation by reference of such document shall not create any implication that there has been no change in our affairs since the date therefor or that the information contained therein is current as of any time subsequent to its date. The information incorporated by reference is considered to be part of this prospectus and should be read with the same care., When we update the information contained in documents that have been incorporated by reference by making future filings with the SEC, the later information filed with or submitted to the SEC will update and supersede such information. We incorporate by reference into this prospectus the documents listed below:

 

(a) Our annual report on Form 20-F for the fiscal year ended December 31, 2018, filed with the SEC on April 1, 2019. (SEC File No. 001-14184);

 

(b) The description of our Ordinary Shares contained in our registration statement on Form 8-A filed with the SEC on December 18, 2006, including any amendment or report filed which updates such description;

 

(c) Form 6-K furnished on August 7, 2019

  

(d) Form 6-K furnished on July 29, 2019

 

(e) Form 6-K furnished on June 3, 2019-Paragraph 1 of the Press Release attached as Exhibit 99.1 thereto.

 

(f) Form 6-K furnished on May 30, 2019-The GAAP financial statements included in the Press Release attached as Exhibit 99.1 thereto.

 

(g) Form 6-K furnished on May 17, 2019-Paragraphs 1-3 of the Press Release attached as Exhibit 99.1 thereto.

 

24

 

  

In addition, we incorporate by reference into this prospectus documents listed below any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act and any reports on Form 6-K submitted to the SEC by the registrant pursuant to the Exchange Act after the date of the initial registration statement and prior to effectiveness of the registration statement that we specifically identify in such forms as being incorporated by reference into the registration statement of which this prospectus forms a part and all subsequent annual reports on Form 20-F filed after the effective date of this registration statement and prior to the termination of this offering and any reports on Form 6-K subsequently submitted to the SEC or portions thereof that we specifically identify in such forms as being incorporated by reference into the registration statement of which this prospectus forms a part, shall be considered to be incorporated into this prospectus by reference and shall be considered a part of this prospectus from the date of filing or submission of such documents.

 

As you read the above documents, you may find inconsistencies in information from one document to another. If you find inconsistencies between the documents and this prospectus, you should rely on the statements made in the most recent document.

 

Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with the SEC. We will deliver to each person (including any beneficial owner) to whom this prospectus has been delivered a copy of any or all of the information that has been incorporated by reference into this prospectus but not delivered with this prospectus. We will provide this information upon written or oral request, and at no cost to the requester. Requests should be directed to:

 

  B.O.S. Better Online Solutions Ltd.
 

20 Freiman Street

Rishon LeZion, 75100, Israel

  Tel.: (+972) 3-954-1000
  Fax: (+972) 3-954-1001
  Attn.: Eyal Cohen, Co-CEO and CFO

 

ENFORCEABILITY OF CIVIL LIABILITIES

  

We are incorporated under the laws of the State of Israel. All of our directors and most of our officers reside outside of the United States. It may be difficult to enforce civil liabilities under the Securities Act and the Exchange Act in original actions instituted in Israel.

 

In addition, it may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws because Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law.

  

25

 

 

However, subject to specified time limitations, Israeli courts may enforce a United States final executory judgment in a civil matter, including a monetary or compensatory judgment in a non-civil matter, obtained after due process before a court of competent jurisdiction according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel. The rules of private international law currently prevailing in Israel do not prohibit the enforcement of a judgment by Israeli courts provided that:

 

  the judgment is enforceable in the state in which it was given;
     
  adequate service of process has been effected and the defendant has had a reasonable opportunity to present his arguments and evidence;
     
  the judgment and the enforcement of the judgment are not contrary to the law, public policy, security or sovereignty of the State of Israel;
     
  the judgment was not obtained by fraud and does not conflict with any other valid judgment in the same matter between the same parties;
     
  an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and
     
  the prevailing law of the foreign state in which the judgment is rendered allows for the enforcement of judgments in Israel.

 

Our subsidiary, Ruby-tech Inc. is our agent to receive service of process in any action against us in any competent court of the United States arising out of this offering or any purchase or sale of securities in connection with this offering.

 

If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at an annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.

 

26

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

B.O.S. BETTER ONLINE SOLUTIONS LTD.

 

 

700,000 of our Ordinary Shares offered by Selling Shareholders

 

PROSPECTUS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

ITEM 8. INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

The Israeli Companies Law, and the Israeli Securities Law, provide that a company may include in its articles of association provisions allowing it to:

 

1. partially or fully, exempt in advance, an office holder of the company from his/her responsibility for damages caused by the breach of his/her duty of care to the company, except for damages caused to the Company due to any breach of such office holder's duty of care towards the company in a “distribution” (as defined in the Israeli Companies Law).
   
2. enter into a contract to insure the liability of an office holder of the company by reason of acts or omissions committed in his/her capacity as an office holder of the company with respect to the following:

 

(a) the breach of his/her duty of care to the company or any other person;

 

(b) the breach of his/her fiduciary duty to the company to the extent he/she acted in good faith and had a reasonable basis to believe that the act or omission would not prejudice the interests of the company;

 

(c) monetary liabilities or obligations which may be imposed upon him/her in favor of other persons;

 

(d) reasonable litigation expenses, including attorneys fees, incurred by the officer as a result of an ongoing administrative enforcement proceeding instituted against him in accordance with the Securities Law; and

 

(e) a payment imposed on the office holder in favor of an injured party as set forth in the Securities Law.

 

3. indemnify an office holder of the company for:

 

(a) monetary liabilities or obligations imposed upon, or actually incurred by, such officer holder in favor of other persons pursuant to a court judgment, including a compromise judgment or an arbitrator’s decision approved by a court, by reason of acts or omissions of such office holder in his or her capacity as an office holder of the company;

 

(b) reasonable litigation expenses, including attorney’s fees, actually incurred by such office holder or imposed upon him or her by a court, in an action, suit or proceeding brought against him or her by or on behalf of us or by other persons, or in connection with a criminal action from which he or she was acquitted, or in connection with a criminal action which does not require criminal intent in which he/she was convicted, in each case by reason of acts or omissions of such office holder in his or her capacity as an office holder; and

 

(c) reasonable litigation expenses, including attorneys’ fees, actually incurred by such office holder (1) due to an investigation or a proceeding instituted against such office holder by an authority competent to administrate such an investigation or proceeding, provided that (i)  it was terminated without the filing of an indictment against such office holder; and without having any monetary charge imposed on such office holder in lieu of criminal proceedings (as such term is defined in the Israeli Companies Law); or (ii) that was terminated without the filing of an indictment against such office holder but with a monetary charge imposed on such office holder in lieu of criminal proceedings of a crime which does not require proof of criminal intent, in each case by reason of acts of such office holder in his or her capacity as an office holder of the company;

  

II- 1

 

  

  (d) expenses, including reasonable litigation expenses and attorneys’ fees, actually incurred by such office holder as a result of a proceeding instituted against such office holder in relation to infringements that may impose financial or administrative sanctions under the Securities Law; and

 

  (e) payments made by the office holder to an injured party ordered by the Administrative Enforcement Committee pursuant to an infringement under the Securities Law.

 

The Israeli Companies Law provides that a company’s articles of association may provide for indemnification of an office holder post-factum and may also provide that a company may undertake to indemnify an office holder in advance, as described in:

 

  i. sub-section 3(a) above, provided such undertaking is limited to and actually sets forth the occurrences, which, in the opinion of the company’s board of directors based on the current activity of the company, are, at the time such undertaking is provided, foreseeable, and to an amount and degree that the board of directors has determined is reasonable for such indemnification under the circumstances; and

 

  ii. sub-sections 3(b) and 3(c) above.

 

The Securities Law provides that a company’s articles of association may provide that a company may undertake to indemnify an office holder in advance, as described in sub-sections 3(d) and 3(e) above.

 

The Israeli Companies Law and Securities Law provide that a company may not indemnify or exempt the liabilities of an office holder or enter into an insurance contract which would provide coverage for the liability of an office holder with respect to the following:

 

1. a breach of his/her fiduciary duty, except to the extent described in sub-section 2(b) above;

 

2. a breach of his/her duty of care, if such breach was done intentionally, recklessly or with disregard of the circumstances of the breach or its consequences, except if such breach is done only with negligence;

 

3. an act or omission done with the intent to unlawfully realize personal gain;

 

4. a fine or monetary settlement imposed upon him/her; or

 

5. an administrative proceeding instituted against the officer holder under the Securities Law, except as described in sub-sections 3(d) and 3(e) above.

 

Under the Israeli Companies Law, the term "office holder" may include a general manager or chief executive officer, executive vice president, vice president or any other managers directly subordinate to the general manager or chief executive officer and any other person fulfilling or assuming any such position or responsibility without regard to such person’s title, or a director.

 

The grant of an exemption, an undertaking to indemnify or indemnification of, and procurement of insurance coverage for, an office holder of a company generally requires, pursuant to the Israeli Companies Law, the approval of our compensation committee and board of directors, and, in certain circumstances, including,  inter alia , (i) if the office holder is a director or chief executive officer; (ii) if the proposed grant of exemption, undertaking to indemnify; or (iii) insurance coverage which deviates from an approved office holder compensation policy, the approval of our shareholders.

 

We have entered into an insurance contract for directors and officers and have procured indemnification insurance for our office holders to the extent permitted by our articles of association.

  

II- 2

 

   

ITEM 9. EXHIBITS

 

Exhibit No.

  Description  
     
4.1*   Securities Purchase Agreement dated as of May 16, 2019 between the Selling Shareholders and the Company. Form of Warrant issued by the Company to the Selling Shareholders.
5.1*   Opinion of Gornitzky & Co., Israeli counsel for B.O.S. Better Online Solutions Ltd., as to the validity of the Ordinary Shares.
23.1*   Consent of Gornitzky & Co. (included in Exhibit 5.1).
23.2*   Consent of Fahn Kanne & Co. Grant Thornton Israel , an independent registered public accounting firm and a member of Grant Thornton.
23.3*   Consent of Kost Forer Gabbay & Kasierer, a Member Firm of Ernst & Young Global, an independent registered public accounting firm.
23.4*   Consent of Alan Moldof, an independent registered public accounting firm
24.1*   Power of Attorney (included in the signature page to this Registration Statement).

 

* filed herewith

 

II- 3

 

  

ITEM 10. UNDERTAKINGS

 

(a) The undersigned registrant hereby undertakes:
   
  (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
     
     

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933 (the “Securities Act”);

 

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

  

  provided, however, that Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
   
  (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
  (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
     
  (4) To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section l5(d) of the Exchange Act that are incorporated by reference in the Form F-3.

  

II- 4

 

  

(5) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

 

(i) If the registrant is relying on Rule 430B:

 

A. each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

 

B. each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

  

(b) For purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section l5(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
   
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the directors, officers and controlling persons of the registrant pursuant to the provisions described under “Item 8. Indemnification of Directors and Officers” above, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

   

II- 5

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Rishon LeZion, in the State of Israel, on August 8, 2019.

 

  B.O.S. Better Online Solutions Ltd.
         
  By: /s/ Yuval Viner   /s/ Eyal Cohen
  Name: Yuval Viner   Eyal Cohen
  Title: Co-Chief Executive Officer   Co-Chief Executive Officer and
Chief Financial Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Yuval Viner and Eyal Cohen, and each of them, his or her true and lawful attorneys-in-fact and agents with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement, together with all schedules and exhibits thereto, and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on, sign and file any supplement to any prospectus filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue hereof.

 

II- 6

 

  

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

 

Signature   Title   Date
         
/s/ Yosi Lahad   Chairman of the Board of Directors   August 8, 2019
Mr. Yosi Lahad        
         
/s/ Yuval Viner   Co-Chief Executive Officer, Director   August 8, 2019
Mr. Yuval Viner    (Principal Executive Officer)    
         
/s/ Eyal Cohen   Co-Chief Executive officer and Chief Financial Officer   August 8, 2019
Mr. Eyal Cohen   (Principal Financial and Accounting Officer)    
         
   /s/ Avidan Zelicovsky  
President, Director
  August 8, 2019
Mr. Avidan Zelicovsky        
         
/s/ Odelia Levanon   Director   August 8, 2019
Ms. Odelia Levanon        
         
/s/ Revital Cohen   Director   August 8, 2019
Ms. Revital Cohen        
         
/s/ Ralph Sassun   Director   August 8, 2019
Mr. Ralph Sassun        
         
/s/ Ziv Dekel   Director   August 8, 2019
Mr. Ziv Dekel        

 

Authorized Representative in the U.S.

 

Ruby-tech, Inc.  
     
By: /s/ Eyal Cohen  
Name: Eyal Cohen  
Title: Co-CEO and Chief Financial Officer  
     
Date: August 8, 2019  

 

 

II-7

 

Exhibit 4.1

 

 

 

 

 

 

 

B.O.S. Better online solutions ltd.

 

sECURITIES PURCHASE AGREEMENT

 

Dated as of

 

May 16, 2019

  

 

 

 

 

 

 

 

share PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is made and entered into as of May 16, 2019 , by and among B.O.S Better Online Solutions Ltd. (the “Company”), and the person(s) and/or entity(ies) listed in Schedule I attached hereto (each, an “ Investor ”, and, severally and not jointly, the “ Investors ”);

 

WHEREAS, the Company wishes to raise capital from the Investors in an aggregate amount of up to US$1,000,000 (the “ Investment Amount ”) by means of the issuance of Ordinary Shares of the Company, nominal value NIS 80.00 each (each, a “ Share ” and collectively, the “ Shares ”) subject to the terms and conditions more fully set forth in this Agreement; and

 

WHEREAS, in connection with the Investors’ purchase of the Shares hereunder, the Company wishes to issue to the Investors such number of warrants to purchase Shares as set forth opposite each Investor’s name in the column labeled “ No. of Warrants ” on Schedule 1 hereto (reflecting 60% warrant coverage), on the terms and conditions hereof; and

 

WHEREAS, subject to the terms and conditions herein, each of the Investors desires to acquire from the Company Shares and Warrants in the amount corresponding to its name as set forth on Schedule I.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors hereby agree as follows:

 

1. PURCHASE AND SALE OF SHARES.

 

1.1 Subject to the satisfaction of the terms and conditions described in this Agreement, at the Closing (as defined below), the Company shall sell and issue to each Investor, and each Investor shall, severally and not jointly, purchase from the Company such number of Shares as set forth opposite its name in Schedule I hereto (the “ Purchased Shares ”) for the corresponding “ Applicable Investment Amount ” set forth therein, reflecting a purchase price per Share equal to $2.5.

 

1.2 At the Closing, the Company shall issue and deliver to the Investors a Warrant in the form attached hereto as Exhibit A (the “ Warrant ”) to purchase such number of Shares as is set forth opposite such Investor’s name in the column labeled “No. of Warrants” (the “ Warrant Shares ”). Subject to the following vesting schedule, the Warrant shall be exercisable for a period of three and a half (3.5) years from the date of issuance (the “ Warrant Issue Date ”). The Warrant’s exercise price shall be $3.30 per Share. The Warrant shall vest and become exercisable with respect to one third of the Warrant Shares upon each of the first, second and third annual anniversary of the Closing (as defined below), provided that on the applicable vesting date, the Investor shall hold all of the Purchased Shares; and provided further that the Warrant shall vest and become exercisable in respect of all of the Warrant Shares in the event one or more shareholders acting together acquire a block of at least 40% of the Company’s issued and outstanding share capital.

  

 

 

 

2. CLOSING. The execution and delivery of this Agreement (and the performance thereof) shall occur on May 16, 2109, upon delivery by facsimile or e-mail of the pdf version of executed signature pages of this Agreement and all other documents, instruments and writings required to be delivered pursuant to this Agreement to Gornitzky & Co., Zion Building, 45 Rothschild Blvd., Tel-Aviv 6578403 Israel Attn: Shlomo Landress, Adv., e-mail: landress@gornitzky.com ; Fax: (972) 3 5606555 (the “ Closing ”). At the Closing(i) each Investor shall deliver to the Company its Applicable Investment Amount, via wire transfer of immediately available funds in accordance with the wire instructions below or bank or cashier’s check; and (ii) the Investors shall be issued the applicable number of Shares as uncertificated shares registered with the Company’s transfer agent, American Stock Transfer & Trust & Co. (“ AST&T ”). As soon as possible following Closing, the Company will deliver to each Investor a printout issued by AST&T reflecting the number of shares purchased by such Investor hereunder.

  

BOS Better Online Solutions Ltd.
The First International Bank of Israel.

42 Rothschild Blvd.

Tel Aviv, Israel 66833

Branch #046
Account No. 880200
Swift Code: FIRBILITXXX
IBAN: IL500310460000000880200

  

Or to:

 

BOS Better Online Solutions Ltd.

Bank Leumi Ltd.

11 Moshe Levy St.

Rishon Le-Zion Industrial Zone, 75707, Israel

Branch#671

Account No. 142900/82

Swift Code: LUMI ILIT TLV

IBAN: IL80 0106 7100 0001 4290 082

 

3. REPRESENTATIONS AND WARRANTIES BY THE COMPANY. The Company hereby represents and warrants to each of the Investors that:

 

3.1 Corporate Organization . The Company is a corporation duly incorporated and validly existing under the laws of Israel, and has the corporate power to own its property and to carry on its business as now being conducted. The Company’s shares are traded on the Nasdaq Capital Market.

  

- 2 -

 

 

3.2 Due Authorization and Valid Issuance . The Company has the corporate power to enter into this Agreement. The Agreement has been, or will have been, at the time of its execution and delivery, duly executed and delivered by the Company. Prior to the Closing of this Agreement, the Company shall have acted to complete all corporate action necessary on its part for the issuance, sale and delivery of the Shares, the Warrants and the Warrant Shares. The Shares being purchased by the Investor hereunder and the Warrant Shares will, upon issuance and payment therefor pursuant to the terms hereof, be duly authorized, validly issued, fully-paid and nonassessable.

 

3.3 Binding Agreement . The Agreement constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance with its terms, except as (i) such enforceability may be limited by bankruptcy, insolvency, reorganization, arrangement, moratorium or similar laws relating to or affecting the rights of creditors and contracting parties generally, (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefore may be brought, and (iii) rights to indemnity and contribution may be limited by Israeli or U.S. state or federal securities laws applicable to the Company or by the public policy underlying such laws.

 

3.4 Non-Contravention . Neither the execution and delivery of the Agreement, nor the consummation of the transactions or the performance of the obligations contemplated hereby will result in any violation or breach of Company’s Articles of Association as currently in effect, board resolutions or shareholders resolutions.

 

3.5 No Consent . To the Company’s best knowledge, and in reliance on the representations of the Investor given in Section 4 hereof, except for reporting obligations and approvals required under applicable securities laws and market regulations and for notices to or approvals by the Israel Innovation Authority (previously the Office of the Chief Scientist) (if required), and filing with the Israeli Registrar of Companies, no consent of any governmental body or third party is required to be made or obtained by the Company in connection with the execution and delivery of the Agreement by the Company or the consummation by the Company of the transactions or the performance of the obligations contemplated hereby by the Company.

 

3.6 Capitalization . The authorized share capital of the Company consists of  6,000,000 Ordinary Shares, nominal value NIS 80.00 per share, of which, as of March 31, 2019, 3,857,790 Ordinary Shares are issued and outstanding.

 

3.7 Financial Statements .

 

The audited consolidated financial statements of the Company as of December 31, 2018 and the related notes thereto, as filed by the Company with the Securities and Exchange Commission (“ SEC ”) under Form 20-F on April 1, 2019, fairly present the financial position of the Company as of their respective dates, and have been prepared in accordance with the books and records of the Company as at the applicable dates and for the applicable periods. Such financial statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods therein specified, except as may be disclosed in the notes to such financial statements, or as may be permitted by the SEC and except as disclosed in the filings the Company made in connection with such statements, if any.

  

- 3 -

 

 

3.8 Legal Proceedings . Except as disclosed in the Company’s public filings, there is no material legal or governmental proceeding pending or, to the knowledge of the Company, threatened to which the Company is or may be a party.

 

3.9 Compliance with Law . To the knowledge of the Company, the business of the Company is conducted in accordance with applicable laws, except to extent that, individually or in the aggregate, would not have a material adverse effect on the Company and its subsidiaries, taken as a whole.

 

3.10 Disclosure . The representations and warranties of the Company contained in this Section 3 as of the date hereof and as of the Closing, and in the Company’s public filings with the SEC do not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements herein, in light of the circumstances under which they are made, not misleading. The representations and warranties contained in this Section 3, are the sole representations and warranties made by the Company with respect to the transaction contemplated by this Agreement, and the Company does not make any other representation or warranty, express or implied.

 

4. REPRESENTATIONS OF THE INVESTOR. Each Investor, severally and not jointly, represents and warrants to the Company that:

 

4.1 Enforceability . (i) The Investor is authorized and qualified and has full right and power to become an investor in the Company, is authorized to purchase the Shares and to perform its obligations pursuant to the provisions hereof, (ii) the person signing the Agreement and any other instrument executed and delivered therewith on behalf of the Investor has been duly authorized by such entity and has full power and authority to do so; , and (iii) such Investor has not been formed for the specific purpose of acquiring an interest in the Company.

 

4.2 Restrictions on Transferability and Hedging; Lock-Up .

 

4.2.1 The Investor understands that (i) the Shares and the Warrant Shares have not been registered under the Securities Act of 1933, or under the laws of any other jurisdiction; (ii) such Shares and Warrant Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act and, where required, under the laws of other jurisdictions or unless an exemption from registration is then available; (iii) there is now no registration statement on file with the SEC with respect to the Shares or the Warrant Shares to be purchased by the Investor.

 

4.2.2 The Investor acknowledges and agrees that the Shares and the Warrant Shares shall bear restrictive legends as counsel to the Company may determine are necessary or appropriate, including without limitation, legends under applicable securities laws similar to the following:

 

“These shares have not been registered under the Securities Act of 1933. The shares have been acquired for investment and may not be sold, transferred, assigned or otherwise disposed of in the absence of an effective registration statement with respect thereto, filed and made effective under the Securities Act of 1933, or an opinion of the Company’s counsel that registration under such Act is not required.”

  

- 4 -

 

 

4.2.3 The Company will not register any transfer of Shares or Warrant Shares not made pursuant to registration under the Securities Act, or pursuant to an available exemption from registration.

 

4.2.4 The Investor agrees not to engage in hedging transactions with regards to the Shares sold pursuant to this Agreement. The Investor further agrees that it will not, during a period commencing upon the Closing and ending on the first anniversary of the Closing (the Lock-Up Period ”) offer, pledge, sell, transfer or otherwise dispose of any of the Shares, Warrants or Warrant Shares, or enter into any derivative transaction that has the economic effect of such sale or transfer.

 

4.3 Investment Purposes . The Shares and the Warrant Shares are being acquired for investment purposes. The Shares and the Warrant Shares are not being purchased with a view to, or for resale in connection with, any distribution or other disposition thereof. The Investor has no present plans to enter into any contract, undertaking, agreement or arrangement for any such resale, distribution or other disposition and it will not divide its interest in the Company’s Shares or Warrant Shares with others, resell or otherwise distribute the Shares or Warrant Shares in violation of U.S. federal or state securities laws or the Israeli Securities Law.

 

4.4 Information and Advice .

 

4.4.1 The Investor has carefully reviewed and understands the risks of a purchase of the Shares and Warrant Shares. In connection with the Investor’s investment in the Company, it has obtained the advice of its own investment advisors, counsel and accountants (the “ Advisors ”). The Investor and its Advisors have reviewed the Company’s public filings and have been furnished with all materials relating to the Company or the offering of the Shares (the “ Offering ”) that they have requested. The Investor and its Advisors have been afforded the opportunity to ask questions of the Company concerning the financial and other affairs of the Company and the conditions of the Offering and to obtain any additional information necessary to verify the accuracy of any representations or information set forth with respect to the Shares and the Warrant Shares.

 

4.4.2 The Company has answered all reasonable inquiries that the Investor and its Advisors have made concerning the Company or any other matters relating to the creation and operations of the Company and the terms and conditions of the Offering.

 

4.5 Sophistication and Risk .

 

4.5.1 It has such knowledge and experience in financial and business matters, that it is capable of evaluating, and has evaluated, the merits and risks of the Offering. By reason of its business or financial experience, it has the capacity to protect its interests in connection with an investment in the Company.

  

- 5 -

 

 

4.5.2 It understands that no Israeli or U.S. federal or state agency has passed upon the Shares or Warrant Shares or made any finding or determination as to the fairness of the transactions contemplated in the Agreement.

 

4.5.3 It understands that the Shares and Warrant Shares are speculative investments, which involve a high degree of risk, including the risk that the Investor might lose its entire amount invested in the Company.

 

4.5.4 It understands that any tax benefits that may be available to the Investor, if any, may be lost through adoption of new laws, amendments to existing laws or regulations, or changes in the interpretation of existing laws and regulations.

 

4.5.5 It has the financial ability to bear the economic risk of its investment in the Company and has adequate net worth and means of providing for the Investor’s current needs and contingencies to sustain a complete loss of the Investor’s investment and has no need for liquidity in the Investor’s investment in the Company.

 

It is an “Accredited Investor,” as such term is defined in Rule 501 of Regulation D under the Securities Act of 1933.

 

4.6 No solicitation . At no time was the Investor presented with or solicited by any leaflet, public promotional meeting, newspaper or magazine article, radio or television advertisement or any other form of general advertising or general solicitation concerning the Offering.

 

4.7 Broker-Dealer . The Investor is not a broker-dealer, nor is it an affiliate of any broker-dealer.

 

4.8 Further Indebtedness . The Investor acknowledges that no provision of the Agreement restricts, or shall be construed to restrict, in any way the ability of the Company to incur indebtedness or to issue share capital or other equity securities (or securities convertible into equity securities) of the Company or to grant liens on its property and assets.

 

4.9 Voting and/or Investment Control over the Investor . Each Investor which is an entity has made available to the Company a list of individuals who have or share voting and/or investment control over such Investor. The Investor acknowledges that the Company may be required to disclose such information in its public filings. Investor shall update such list as may reasonably be requested by the Company from time to time to comply with the Company’s disclosure obligation and/or with a request for such information from any regulatory body.

 

4.10 Independent Investment . T  The Investor has not agreed to act with any other person for the purpose of acquiring, holding, voting or disposing of the Shares or Warrant Shares purchased hereunder, and is acting independently with respect to its investment in the Shares and Warrant Shares. The obligations of the Investor under the Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under the Agreement. Nothing contained herein nor any action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors, or any of them, as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors, or any of them, are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Agreement.

  

- 6 -

 

 

4.11 Holdings . Schedule I attached hereto reflects the holdings of the Company’s shares by the Investor and its affiliates as of the date hereof, and as of the Closing.

 

4.12 Availability of Exemptions . The Investor understands that the Shares are being offered and sold in reliance on a transactional exemption or exemptions from the registration requirements of Israeli and U.S. federal and state securities laws and the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Investor set forth herein in order to determine the applicability of such exemptions and the suitability of the Investor to acquire the Shares and the Warrant Shares.

 

4.13 Disclosure . The representations and warranties of the Investor contained in this Section 4 as of the date hereof and as of the Closing, do not contain any untrue statement of a material fact or omit to state a material fact required to be stated herein or necessary to make the statements herein, in light of the circumstances under which they are made, not misleading. The Investor understands and confirms that the Company will rely on the foregoing representations in effecting the transaction contemplated in the Agreement and other transactions in securities of the Company.

 

5. CONDITIONS OF INVESTOR’S OBLIGATION AT THE CLOSING. The obligation of each Investor to purchase Shares is subject to the fulfillment or waiver by the Investor prior to or on the date of the Closing of the conditions set forth in this Section 5. In the event that any such condition is not satisfied to the satisfaction of the Investor, then the Investor shall not be obligated to proceed with the purchase of such securities.

 

5.1 Representations and Warranties . The representations and warranties of the Company under this Agreement shall be true in all material respects as of the Closing, with the same effect as though made on and as of such date.

 

5.2 Compliance with Agreements . The Company shall have performed and complied in all material respects with all agreements or conditions required by this Agreement to be performed and complied with by it prior to or as of the Closing.

 

5.3 No Injunction . No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

5.4 Government Approvals . The Company shall have received all necessary governmental approvals with respect to the transactions contemplated hereby.

  

6. CONDITIONS OF THE COMPANY’S OBLIGATION AT THE CLOSING. The obligation of the Company to issue the Shares to each Investor is subject to the fulfillment or waiver by the Company prior to or on the Closing of the conditions set forth in this Section 6. In the event that any such condition is not satisfied to the satisfaction of the Company, then the Company shall not be obligated to proceed with the sale of the securities under this Agreement.

  

- 7 -

 

 

6.1 Representations and Warranties . The representations and warranties of the Investor under this Agreement shall be true in all material respects as of the Closing, with the same effect as though made on and as of such date.

 

6.2 Compliance with Agreements . The Investor shall have performed and complied in all respects with all agreements or conditions required by this Agreement to be performed and complied with by it prior to or as of the Closing.

 

6.3 No Injunction . No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

6.4 Delivery of Purchase Amount . The Investor shall have delivered to the Company its Purchase Amount for the Shares at the Closing Date.

 

6.5 Government Approvals . The Company shall have received all necessary governmental approvals with respect to the transactions contemplated hereby. The Investor shall have executed any confirmations and undertakings required by the Israel Innovation Authority (previously the Office of Chief Scientist), if applicable.

 

7. REGISTRATION . Not later than 180 days from the date of the Closing of the Share Purchase Agreement, the Company shall prepare and file with the SEC a Registration Statement on Form F-3 covering the Purchased Shares and the Warrants Shares (collectively, the “ Registrable Securities ”) for an offering to be made on a continuous basis pursuant to Rule 415 under the Securities Act of 1933 (the “ Securities Act ”). The Company shall cause the Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof and shall use its reasonable commercial efforts to keep the Registration Statement continuously effective under the Securities Act until the date which is the earlier of: (i) the date when all Registrable Securities have been sold; (ii) 4 years from the date hereof. The expenses incurred in connection with such registration shall be borne and paid by the Company.

  

- 8 -

 

 

8. CONFIDENTIALITY. Any information disclosed to the Investor or its Advisors, which has not previously been made available to the general public by the Company, if any, shall be considered Confidential Information. The Investor acknowledges the confidential nature of the Confidential Information it may have received, and agrees that the Confidential Information is the valuable property of the Company. The Investor agrees that it and its Advisors shall not reproduce any of the Confidential Information without the prior written consent of the Company, nor shall they use any Confidential Information for any purpose except as permitted by and in the performance of this Agreement, or divulge all or any part of the Confidential Information to any third party. The confidentiality obligations undertaken by the Investor hereunder will remain in full force and effect regardless of the execution and consummation or termination of this Agreement.

 

9. MISCELLANEOUS.

 

9.1 Amendments. This Agreement may be modified, supplemented or amended only by a written instrument executed by the parties hereto.

 

9.2 Notices . Any notice that is required or provided to be given under this Agreement shall be deemed to have been sufficiently given and received for all purposes, (i) when delivered in writing by hand, upon delivery; (ii) if sent via facsimile or email, upon transmission (and if transmitted and received on a non-business day, on the first business day following transmission), (iii) seven (7) business days (and fourteen (14) business days for international mail) after being sent by certified or registered mail, postage and charges prepaid, return receipt requested, or (iv) three (3) business days after being sent by internationally overnight delivery providing receipt of delivery, to the following addresses:

 

if to the Company, B.O.S Better Online Solutions Ltd., 20 Freiman Street, Rishon Lezion, 75101 Israel Attn: Mr. Eyal Cohen, Co-CEO and CFO, facsimile: (972) 3 954-1003, with a copy (that shall not serve as notice) to Gornitzky & Co., Zion Building, 45 Rothschild Blvd., Tel-Aviv 6578403 Israel Attn: Shlomo Landress, Adv., e-mail: landress@gornitzky.com; Fax: (972) 3 5606555; or at any other address designated by the Company to the Investor in writing;

 

if to the Investor, to its address listed on Schedule I hereto or at any other address designated by the Investor to the Company in writing.

 

9.3 Survival of Representations and Warranties . All representations and warranties contained herein shall survive after the execution and delivery of this Agreement or such certificate or document, as the case may be, for a period of 24 months from the date hereof. All covenants and agreements in the Agreement shall survive in accordance with their terms. This Section shall survive the termination of this Agreement for any reason.

 

9.4 Delays or Omissions; Waiver . Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party under this Agreement shall impair any such right, power or remedy of such party nor shall it be construed to be a waiver of any breach or default, or an acquiescence thereto, or of a similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party hereto of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.

  

- 9 -

 

 

9.5 Other Remedies . Any and all remedies herein expressly conferred upon a party shall be deemed cumulative with, and not exclusive of, any other remedy conferred hereby or by law on such party, and the exercise of any one remedy shall not preclude the exercise of any other.

 

9.6 Entire Agreement . This Agreement and the exhibits and schedules hereto, constitute the entire understanding and agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous agreements or understandings, inducements or conditions, express or implied, written or oral, between the parties with respect hereto and thereto.

 

9.7 Headings. All section headings herein are inserted for convenience only and shall not modify or affect the construction or interpretation of any provision of this Agreement.

 

9.8 Severability . Should any one or more of the provisions of this Agreement (including its exhibits and schedules) be determined to be illegal or unenforceable, all other provisions of this Agreement shall be given effect separately from the provision or provisions determined to be illegal or unenforceable and shall not be affected thereby. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision, which will achieve, to the extent possible, the economic, business and other purposes of the void or unenforceable provision.

 

9.9 Assignment . This Agreement may not be assigned in whole or in part by the Investor without the prior written consent of the Company.

 

9.10 Governing Law and Venue . This Agreement shall be construed in accordance with and governed by the internal laws of the State of Israel, without regard to conflict of laws provisions. Any dispute arising under or in relation to this Agreement shall be adjudicated in the competent court of Tel Aviv-Jaffa district only, and each of the parties hereby submits irrevocably to the exclusive jurisdiction of such court.

 

9.11 Counterparts . This Agreement may be executed concurrently in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

9.12 Further Actions. At any time and from time to time, each party agrees, without further consideration, to take such actions and to execute and deliver such documents as may be reasonably necessary to effectuate the purposes of this Agreement.

 

(Remainder of page intentionally left blank.)

   

- 10 -

 

 

IN WITNESS WHEREOF , the undersigned have executed and delivered this Agreement as of the date first set forth above.

 

COMPANY:

    

B.O.S. BETTER ONLINE SOLUTIONS LTD.  
   
By:    
  Name:    
  Title:    

 

INVESTOR:

 

By:    
  Name:     
  Title:    

   

- 11 -

 

  

Schedule I

 

INVESTOR’S
NAME AND
  APPLICABLE
INVESTMENT
    NO. OF
PURCHASED
    NO. OF
WARRANTS
 
ADDRESS   AMOUNT     SHARES     PURCHASED  
Premier Financial Concepts LLC   USD 300,000       120,000       72,000  
Rodney Speight   USD 50,000       20,000       12,000  
Ralph J. Fratus Jr   USD 100,000       40,000       24,000  
Michele Roverto Manago   USD 50,000       20,000       12,000  
The John C. & Desiree A. Coats Trust dated 03/29/04   USD 50,000       20,000       12,000  
The Walter and Laura Whetstine Revocable Living Trust dated 10/12/2010   USD 50,000       20,000       12,000  
Woodman Revocable Trust dated 08/12/12   USD 50,000       20,000       12,000  
Todd M. Felte   USD 50,000       20,000       12,000  
Kristi Dorman   USD 50,000       20,000       12,000  
Dean Amato   USD 100,000       40,000       24,000  
Dana W. Amato   USD 150,000       60,000       36,000  

  

- 12 -

 

 

THIS WARRANT AND THE ORDINARY SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE ORDINARY SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO B.O.S. BETTER ONLINE SOLUTIONS LTD. THAT SUCH REGISTRATION IS NOT REQUIRED.

 

Right to Purchase up to ________ Ordinary Shares of
B.O.S. Better Online Solutions Ltd.
(subject to adjustment as provided herein)

 

ORDINARY SHARES PURCHASE WARRANT

 

No. _________________ Issue Date: May ___, 2019 

 

B.O.S. BETTER ONLINE SOLUTIONS LTD. a company incorporated under the laws of the State of Israel hereby certifies that, for value received, ___________, or assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company (as defined herein) up to _________ fully paid and nonassessable Ordinary Shares (as hereinafter defined), NIS 80.00 nominal value per share (the “Warrant Shares”), at the exercise price of $3.30 per Ordinary Share (the “Exercise Price”). The number and character of such Ordinary Shares and the Exercise Price per share are subject to adjustment as provided herein.

 

1. As used herein the following terms, unless the context otherwise requires, have the following respective meanings:

 

(a) The term “Company” shall include B.O.S. Better Online Solutions Ltd. and any corporation which shall succeed, or assume the obligations of, B.O.S. Better Online Solutions Ltd. hereunder.

 

(b) The term “Other Securities” refers to any securities of the Company or any other person (corporate or otherwise) which the Holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise of the Warrant, in lieu of or in addition to Ordinary Shares, or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Ordinary Shares or Other Securities pursuant to Section 3 or otherwise.

 

- 13 -

 

 

Capitalized terms used herein without definition shall have the meanings ascribed to such terms in that Securities Purchase Agreement dated as of the date hereof by and among the Company and the Investor (as defined therein).

 

2. Exercise of Warrant .

 

2.1 Term. This Warrant shall be subject to a three year annual vesting and may be exercised as follows: (i) commencing May _______ 2020 with respect to up to _______ Ordinary Shares of the Company; (ii) commencing May ____2021 with respect to up to an additional _______ Ordinary Shares of the Company; and (iii) commencing May ___2022 with respect to up to an additional ________Ordinary Shares of the Company (each such date, a “ Vesting Date ”), provided that on the applicable Vesting Date the Holder shall be the owner of all of the Ordinary Shares the Holder has acquired from the Company on the date hereof (the “ Purchased Shares ”). The Warrant shall automatically expire and no longer be exercisable on November ____, 2022 or, with respect to any portion of the Warrant not previously vested as described above, upon the earlier sale by the holder of all or part of the Purchased Shares.

  

2.2 Shares Issuable upon Exercise . The Holder shall be entitled to receive, upon exercise of this Warrant in whole or in part, by delivery of an original or fax copy of an exercise notice in the form attached hereto as  Exhibit A  (the “Exercise Notice”) and payment in accordance with Section 2.2 below, Ordinary Shares of the Company (the “Warrant Shares”), subject to adjustment pursuant to Section 4.

 

2.3 Company Acknowledgment . The Company will, at the time of the partial exercise of the Warrant, upon the request of the Holder hereof acknowledge in writing its continuing obligation to afford to such Holder any rights to which such Holder shall continue to be entitled after such partial exercise in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to such Holder any such rights.

  

- 14 -

 

 

3. Procedure for Exercise .

 

The Company agrees that the Warrant Shares purchased upon exercise of this Warrant shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered and payment made for such shares in accordance herewith. As soon as practicable after the exercise of this Warrant in full or in part, and in any event within three (3) business days thereafter, the Company at its expense (including the payment by it of any applicable issue taxes) will cause to be issued in the name of and delivered to the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in compliance with applicable securities laws, such number of duly and validly issued, fully paid and nonassessable Warrant Shares (or Other Securities) to which the Holder shall be entitled on such exercise, as uncertificated shares registered with the Company’s transfer agent.

 

4. Payment of Exercise Price .

 

Payment shall be made in cash, by wire transfer to a bank account the details of which shall have been provided by the Company to the Holder in writing or by certified or official bank check payable to the order of the Company, of the amount equal to the applicable aggregate Exercise Price for the number of Ordinary Shares specified in the Exercise Notice (as such exercise number shall be adjusted to reflect any adjustment in the total number of Warrant Shares issuable to the Holder per the terms of this Warrant) and the Holder shall thereupon be entitled to receive the applicable number of duly authorized, validly issued, fully-paid and non-assessable Warrant Shares (or Other Securities) determined as provided herein.

 

5. Fractional Shares .

 

This Warrant may not be exercised for fractional shares. In lieu of fractional shares the Company shall make a cash payment therefor based upon the Exercise Price then in effect.

 

6. Effect of Reorganization, Etc.; Adjustment of Exercise Price.

 

6.1 Reorganization, Consolidation, Merger, Etc. In case at any time or from time to time, the Company shall (a) effect a reorganization, (b) consolidate with or merge into any other person, including the sale of substantially all of the Company’s outstanding share capital to a corporate third party, in consideration for such third party’s securities, or (c) transfer all or substantially all of its properties or assets to any other person under any plan or arrangement contemplating the dissolution of the Company, then, in each such case, as a condition to the consummation of such a transaction, proper and adequate provision shall be made by the Company whereby the Holder of this Warrant, on the exercise hereof as provided in Sections 2 and 3 at any time after the consummation of such reorganization, consolidation or merger or the effective date of such dissolution, as the case may be, shall receive, in lieu of the Ordinary Shares issuable on such exercise prior to such consummation or such effective date, the shares and Other Securities and property (including cash) to which such Holder would have been entitled upon such consummation or in connection with such dissolution, as the case may be, if such Holder had so exercised this Warrant, immediately prior thereto, all subject to further adjustment thereafter as provided in Section 4.

  

- 15 -

 

 

6.2 Extraordinary Events Regarding Ordinary Shares. In the event that the Company shall (a) issue additional Ordinary Shares as a dividend or other distribution on outstanding Ordinary Shares, (b) subdivide its outstanding Ordinary Shares, or (c) combine its outstanding Ordinary Shares into a smaller number of Ordinary Shares, then, in each such event, the Exercise Price shall, simultaneously with the happening of such event, be adjusted by multiplying the then Exercise Price by a fraction, the numerator of which shall be the number of Ordinary Shares outstanding immediately prior to such event and the denominator of which shall be the number of Ordinary Shares outstanding immediately after such event, and the product so obtained shall thereafter be the Exercise Price then in effect. The Exercise Price, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described herein in this Section 3.2. The number of Ordinary Shares that the Holder of this Warrant shall thereafter, on the exercise hereof be entitled to receive shall be increased or decreased, as the case may be, to a number determined by multiplying the number of Ordinary Shares that would otherwise (but for the provisions of this Section 3.2) be issuable on such exercise by a fraction of which (a) the numerator is the Exercise Price that would otherwise (but for the provisions of this Section 3.2) be in effect, and (b) the denominator is the Exercise Price in effect on the date of such exercise.

 

6.3 Good Faith . All determinations with respect to adjustments by the Company hereunder shall be made by the Board of Directors in good faith.

 

7. Certificate as to Adjustments . In each case of any adjustment or readjustment in the Ordinary Shares (or Other Securities) issuable on the exercise of the Warrant, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of the Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based.

 

8. Reservation of Shares, Etc., Issuable on Exercise of Warrant . The Company will at all times reserve and keep available, solely for issuance and delivery on the exercise of the Warrant, Ordinary Shares (or Other Securities) from time to time issuable on the exercise of the Warrant.

  

- 16 -

 

 

9. Representations of the Company . The Company represents that (i) all corporate actions on the part of the Company, its officers, directors and shareholders necessary for the sale and issuance of the Warrant Shares pursuant hereto and the performance of the Company’s obligations hereunder were taken prior to and are effective as of the issue date of this Warrant; (ii) the Warrant Shares are duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable and not subject to any preemptive rights, and (iii) the execution and delivery of this Warrant are not, and the issuance of the Warrant Shares upon exercise of this Warrant in accordance with the terms hereof will not be, inconsistent with the Company’s Articles of Association, do not and will not contravene any law, governmental rule or regulation, or, to the Company’s knowledge, any judgment or order applicable to the Company, and, except for consents that have already been obtained by the Company or except as would not have a Material Adverse Effect, do not and will not conflict with or contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which the Company is a party or by which it is bound, or require the consent or approval of, the giving of notice to, the registration with or the taking of any action in respect of or by any government authority or agency or other person.. as used herein, “Material Adverse Effect” means any material adverse effect on the business, properties, assets, operations, prospects, results of operations or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole.

 

10. Representations and Warranties by the Holder . The Holder represents and warrants to the Company as follows:

 

10.1 Holder understands that the Warrant is being offered and sold pursuant to an exemption or exemptions from registration requirements of Israeli and US Federal and state securities laws and that the Company is relying upon the truth and accuracy of Holder’s representations contained in that Securities Purchase Agreement of even date herewith, including, without limitation, that the Holder is an “Accredited Investor” within the meaning of Regulation D under the Securities Act of 1933.

 

10.2 Holder has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. Holder is able to bear the economic risk of this investment.

 

10.3 Holder is acquiring the Warrant and the Ordinary Shares issuable upon exercise of the Warrant for its own account for investment only, and not as a nominee or agent and not with a view towards or for resale in connection with their distribution.

  

- 17 -

 

 

11. Assignment; Exchange of Warrant . Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred in whole by any registered Holder hereof (a “Transferor”) in whole or in part. On the surrender for exchange of this Warrant, with the Transferor’s endorsement in the form of  Exhibit B  attached hereto (the “Transferor Endorsement Form”) and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable securities laws, which shall include, without limitation, a legal opinion from the Transferor’s counsel that such transfer is exempt from the registration requirements of applicable securities laws, the Company at its expense (but with payment by the Transferor of any applicable transfer taxes) will issue and deliver a new Warrant of like tenor, in the name of the transferee specified in such Transferor Endorsement Form (each a “Transferee”), calling in the aggregate on the face thereof for the number of Ordinary Shares called for on the face of the Warrant so surrendered by the Transferor. Notwithstanding the foregoing, no opinion of counsel or “no-action” letter shall be necessary for a transfer without consideration by a Holder to any other entity which controls, is controlled by or is under common control with the Holder.

 

12. Replacement of Warrant . On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

 

13. Rights of Shareholders . No Holder shall be entitled, in its capacity as a Warrant holder only, to vote or receive dividends or be deemed the holder of the Ordinary Shares or any Other Securities of the Company, which may at any time be issuable upon the exercise of this Warrant for any purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a shareholder of the Company or any right to vote for the election of directors or upon any other matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of shares, reclassification of shares, change of nominal value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until the Warrant shall have been exercised and the Ordinary Shares issuable upon the exercise hereof shall have become deliverable, as provided herein.

  

- 18 -

 

 

14. Transfer on the Company’s Books . Until this Warrant is transferred on the books of the Company, the Company may treat the registered holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

 

15. Notices, Etc . All notices and other communications from the Company to the Holder of this Warrant shall be deemed to have been sufficiently given and received for all purposes, (i) when delivered in writing by hand, upon delivery; (ii) if sent via facsimile, upon transmission and electronic confirmation of receipt (and if transmitted and received on a non-business day, on the first business day following transmission and electronic confirmation of receipt), (iii) seven (7) business days (and fourteen (14) business days for international mail) after being sent by certified or registered mail, postage and charges prepaid, return receipt requested, or (iv) three (3) business days after being sent by internationally overnight delivery providing receipt of delivery, to the address as may have been furnished to the Company in writing by such Holder or, until any such Holder furnishes to the Company an address, then to, and at the address of, the last Holder of this Warrant who has so furnished an address to the Company.

 

16. Miscellaneous . This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant shall be governed by and construed in accordance with the laws of the State of Israel without regard to principles of conflicts of laws. Any dispute arising under or in relation to this Agreement shall be adjudicated in the competent court of Tel Aviv-Jaffa district only, and each of the parties hereby submits irrevocably to the exclusive jurisdiction of such court. In the event that any provision of this Warrant is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision, which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Warrant. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

[BALANCE OF PAGE INTENTIONALLY LEFT BLANK;

 

SIGNATURE PAGE FOLLOWS]

  

- 19 -

 

 

IN WITNESS WHEREOF, this Warrant is executed as of the date first written above.

 

B.O.S. BETTER ONLINE SOLUTIONS LTD.

 

By:     By:  
     
Name:      Name:  
     
Title:     Title:  

  

- 20 -

 

 

EXHIBIT A

 

FORM OF SUBSCRIPTION 
(To Be Signed Only on Exercise of Warrant)

 

To: B.O.S. Better Online Solutions Ltd.

 

Attention:   Co-CEO and Chief Financial Officer

 

The undersigned, pursuant to the provisions set forth in the attached Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):

 

________        ________ Ordinary Shares covered by such Warrant;

 

☐☐ The undersigned herewith makes payment of the full Exercise Price for such Ordinary Shares at the price per share provided for in such Warrant, which is $_____________.

 

Such payment takes the form of (check applicable box or boxes):

 

  $__________ by wire transfer of lawful money of the United States; and/or

 

  $__________ by certified or official bank check payable to the order of the Company

  

The undersigned requests that shares be issued in the name of, and delivered to ______________________________________________ whose address is _________________________________________________________________________.

 

The undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Ordinary Shares under the Securities Act of 1933, as amended (the “Securities Act”) or pursuant to an exemption from registration under the Securities Act.

     

Dated: ___________    
    (Signature must conform to name of
Holder as specified on the face of the Warrant)

 

Address:  
   

   

- 21 -

 

 

EXHIBIT B

 

FORM OF TRANSFEROR ENDORSEMENT  
(To Be Signed Only on Transfer of Warrant)

 

For value received, the undersigned hereby sells, assigns, and transfers unto the person named below under the heading “Transferee” the right represented by the within Warrant to purchase the number of Ordinary Shares of B.O.S Better Online Solutions Ltd. into which the within Warrant relates and appoints each such person attorney-at-fact to transfer its respective right on the books of B.O.S. Better Online Solutions Ltd. with full power of substitution.

  

NAME OF TRANSFEREE   ADDRESS

 

     
DATED: _______________ (SIGNATURE MUST CONFORM TO NAME
OF HOLDER AS SPECIFIED ON THE FACE
OF THE WARRANT)

  

ADDRESS:  
   
   
   
   

 

ACCEPTED AND AGREED:
 

[TRANSFEREE]

 

By:    
     
Name:    
     
Title:    

 

 

- 22 -

 

Exhibit 5.1

 

 

To: August 8, 2019

 

B.O.S. Better Online Solutions Ltd.

20 Freiman Street

Rishon LeZion, 7535825

Israel

 

Re: Registration Statement on Form F-3

 

Ladies and Gentlemen:

 

We have acted as Israeli counsel to B.O.S. Better Online Solutions Ltd. (the “ Company ”) in connection with the registration statement on Form F-3 (the “ Registration Statement ”) filed with the Securities and Exchange Commission (the “ Commission ”) on or about the date hereof. The Registration Statement relates to the registration of:

 

1. 400,000 Ordinary Shares, nominal value NIS 80.00 per share (the “ Issued Shares ”);

 

2. 300,000 Ordinary Shares, nominal value NIS 80.00 per share (the “ Warrant Shares ”) that are issuable upon exercise of Company warrants (the “ Warrants ”).

 

The Issued Shares and the Warrants were issued to the Selling Shareholders listed in the Registration Statement pursuant to a Securities Purchase Agreement dated as of May 16, 2019.

 

In connection therewith, we have examined the originals, or photostatic or copies, certified or otherwise identified to our satisfaction of such corporate records, agreements, documents and other instruments and have made such investigation of matters of fact and law, as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.

 

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as photostatic or certified copies, and the authenticity of the originals of such latter documents. As to all questions of fact material to the opinions set forth herein, we did not independently establish or verify such facts and we have relied, without independent investigation, upon statements, certificates or comparable documents of officers and representatives of the Company and upon certificates of public officials. We have considered such questions of Israeli law as we have deemed necessary for the purpose of rendering this opinion.

 

Tel-Aviv: 45 Rothschild Blvd., Herzliya: 1 Abba Eban Blvd

Phone: +972-3-7109191 Fax: +972-3-5606555

E-mail address: office@gornitzky.com P.O.B 29141 Tel-Aviv 6578403 Israel

 

Advocates&Notaries

www.gornitzky.com

ESTABLISHED - 1938

Eric J. Gornitzky           (1921 – 1997)

Boaz Nahir                   (1930 – 2006)

Ariel Zelichov              (1955 – 2009)

Dalia Ronen                 (1956 – 2000)

Hagar Alon-Windman  (1978 – 2013)

Daphna Talgam           (1954 – 2015)

*     Member of the New York State Bar

**    Member of the New York State Bar and Massachusetts Bar

***   Solicitor in England & Wales

****  Solicitor in the State of Victoria, Australia

Pinhas Rubin

Moriel Matalon

Jack Smith

Eyal Marom

Ofer Tzur

Itay Geffen

Eyal Raz

Erez Harel

Chaim Y. Friedland*

Lior Porat

Yaron Elhawi

Sharon Werker-Sagy

Elite Elkon

Eli Elya

Shlomo Cohen

Daniel Paserman(CPA)

Gil Grady (CPA)

Noam Ronen

Eli Cohen

Kfir Yadgar

Timor Belan

Avi D. Pelossof

Maya Sabari

Aviram Handel

Daniel Marcus

Shlomo Landress*

Yair Shiloni

Joseph D. Gross***

Harel Shaham

Ari Fried**

Orly Tenennbaum

Idan Baki

Shiri Shani

Sagit Ohana-Livne

Avner Finkelshtein

Michael Ayalon

Nurit Traurik

Tamar Cohen

Lior Relevy

Ofer Fleischer

Ziv Rotenberg

Adi Ben-Hur Efroni

Inbal Zackay-Horev

Itai Itzkovich

Ronit Rozenstein-Barel

Shlomo Aviad Zider

Ori Yitzhak

Itzchak Lazar

Yiftach Farber

Adi Nahmias-Twina

Inbal Badner

Asaf Avtuvi

Yehonatan Raff

Uri Heller

Oded Uni

Nir Keidar

Assaf Harel

Hila Shimon

Ehud Katzenelson

Gila Ponte-Shlush***

Daniel Lasry

Saray Aharony (CPA)

Yoad Cohavy

Sarit Naaman Shaag

Itay Rubin

Shimon Moyal

Maya Hoftman

Assaf Prussak

Avi Meer*

Shahar Eisner

Daniel Skald (CPA)

Reut Oshaya Holzer

Sharon Zeitouni

Ilana Zibenberg

Marina Goldshtein

Anat Schnur Rabinovich

Ariel Zeewi

Nir Erez

Nitsan Litwak

Lior Baran

Neta Peled

Alon Peled

Yoav Meer*

Joanna Yanowsky

Sagi Padureanu

Itamar Ben Yehuda

Lior Grinblat

Amit Levy

Tal Sela

Nuna Lerner

Carolyn Zeimer Vigodny

Shirin Gabbay-Metzger

Elinor Lavie Vardi

Noga Haruvi

Yael Kleinman

Shani Sahar

Inbar Barak-Bilu (CPA)

Adi Haya Raban

Liron Gilor

Nimrod Saville

Dana Suidman

Dan Fisher

Yechiel Zipori

Amnon Biss

Tom Alkalay

Shimrit Moshe

Shahar Oshri

Idan Zohar

Tamar Barchad (CPA)

Tsefi Feldman

 

 

 

 

Based upon and subject to the foregoing and to the other qualification and limitations set forth herein, and subject to the effectives of the Registration Statement under the Securities Act of 1933, as amended (the “ Act ”), we are of the opinion that:

 

1. The Issued Shares are duly authorized, validly issued, fully paid and non-assessable.

  

2. The Warrant Shares, upon issuance following exercise of the Warrants in accordance with their terms, shall be duly authorized, validly issued, fully paid and nonassessable.

 

We are members of the Bar of the State of Israel and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws of Israel and have not, for the purpose of giving this opinion, made any investigation of the laws of any other jurisdiction than Israel. This opinion letter is effective only as of its date and the opinions expressed herein are based upon the law in effect (and published or otherwise generally available) on the date hereof, and we assume no obligation to revise or supplement this opinion letter should such law be changed by legislative action, judicial decision or otherwise. This opinion letter is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters. In addition, we render no opinion in relation to any representation made or given in the Registration Statement.

 

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement and to the reference to our firm under the caption, “Validity of Securities” in the related prospectus. In giving such consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

  

    Very truly yours,
     
    /s/ Gornitzky & Co.
    Gornitzky & Co.

Nir Knoll*

Natalie Dragot

Shani Weiss

Samuel Berkowitz****

Marina Portugalov

Adi Shoval*

Maor Israeli

Moshe Sevi

Moran Ben Moshe

Yaad Gordon

Hagar Peleg

Smadar Ron

Noa Schweitzer Amar

Roni Sharon Aviram

Nofar Arad

Ayala Livni Shoham

Shira Plotnik

Yehonatan Prussak

Elona Lerner

Maya Rechnitz

Raz Karni

Zeev Bienenstock

Daniel Barlev

Maya Dvir

Alex Lazarovich

Inbal Navon

Alex Feldsher

Lior Sharabi

Netanel Kahana

Yuval Kaplan

Nir Moses (CPA)

Niran Dor

Assaf Hasson

Karin Avichail

Noy Greenberg

Asaf Alterman

Karin Blank

Netalee Aviv

Amir Tzemach

Liron Karass

Dalia Karzbrun (CPA)

Sharon Reingwirtz

Alon Shecheransky

Noa Even Sapir

Dafna Sidkiyahu

Amit Kappon

Avigail Labaton

Moran Ben Dayan (CPA)

Tomer Basson

Amit Ron

Inbal Ronel

Sharon Strauss

Yitzhak Hefetz

Roy Eilon

Ben Peleg

Shira Abergel-Hajaj

Shmuel Matan Ben-Guigui

Niv Braverman

Astar Shechter

Shahar Schleifer

Anat Zehavi

Lilach Lotan

Moshe Yaakoby

Teddy Chouraki

Hana Atias

Laura Tal Hadar

Oren Meiri

Netanel Nehemya

Anat Primovich

Omer Rousso Haezrachy

Omer Razin

Ran Shamia

Lilach Shamir (CPA)

Coral Ashkeloni

Danit Yekutiel

Inbar Nisim Katz

Omri Katz

Amit Timor

Shir Hershkovits

Toot Salles

Hila Sabah

Inbar Boiangio

David Chester

Michal Lavi-Sneh

Netta Oyerbach

Koral Zellinger

Lee Cohen

Natali Shaybak

Stav Tayar

David Chekroun

Tamir Bar-Tov

Amit Perets

Gali Havkin

Amit Cohen

Yoel Lavie

Tomer Felach

Dr. Yehonatan Shiman

Adam Spiegel

Omer Goldenberg

Shai Czarni

Edward Dizengoff

Karin Shlush

Tom Rosenberg

____________

Zvi Ephrat, Senior Counsel

Zvi Sohar, Of-Counsel

Rani M. Haj-Yachya, Of-Counsel

 

- 2 -

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have issued our report dated April 1, 2019, with respect to the consolidated financial statements of B.O.S. Better Online Solutions Ltd. included in the Annual Report on Form 20-F for the year ended December 31, 2018, which are incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement, and to the use of our name as it appears under the caption “Experts.”

  

/s/ FAHN KANNE & CO. GRANT THORNTON ISRAEL

 

Tel Aviv, Israel

 

August 8, 2019

Exhibit 23.3

  

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the reference to our firm under the caption “Experts” in this Registration Statement on Form F-3 and related prospectus of B.O.S Better Online Solutions Ltd. (“ BOS ”) and to the incorporation by reference therein of our report dated March 26, 2017 with respect to the consolidated financial statements of BOS for the year ended December 31, 2016 included in its annual report on Form 20-F for the year ended December 31, 2018, filed with the Securities and Exchange Commission.

 

    /s/ KOST, FORER GABBAY & KASIERER
   

KOST FORER GABBAY & KASIERER

A Member Firm of Ernst & Young Global

 

Tel Aviv, Israel

August 5, 2019

 

Exhibit 23.4

 

CONSENT OF INDEPENDENT ACCOUNTING FIRM

 

We hereby consent to the reference to our firm under the caption “Experts” in this Registration Statement on Form F-3 and related prospectus of B.O.S Better Online Solutions Ltd. (“ BOS ”) and to the incorporation by reference therein of our report dated July 27, 2019 with respect to the consolidated financial statements of Imdecol Ltd. for the year ended December 31, 2018, included in BOS’ report on Form 6-K, filed with the Securities and Exchange Commission on July 29, 2019.

 

/s/ Alan Moldof  

 

Jerusalem, Israel

August 5, 2019